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I. Summary 
 
Ribosomes are gigantic ribonucleoprotein particles which catalyze the polymerization of amino 
acids. There is a wealth of genetic and biochemical evidence to support the concept that the 
rRNA plays a pivotal role in ribosome functions, e.g. mRNA decoding, tRNA binding, peptidyl 
transfer, subunit association. The ribosome is target for a plethora of antibacterial agents 
including aminoglycosides, macrolides, ketolides, oxazolidinones, lincosamides. These 
compounds target different ribosomal functions like peptidyl transfer, mRNA decoding, tRNA 
translocation. Ribosomal antibiotics mainly bind to the rRNA which typically shows a high degree 
of phylogenetic sequence conservation within the drug binding pocket. It is unclear whether the 
minor sequence variations present in the bacterial drug-binding site affect antibiotic susceptibility 
and/or resistance development. Previously, limitations in genetic manipulation did not allow to 
study the effect of rRNA sequence variations on bacterial drug susceptibility in isogenic mutants. 
Rather, investigations were limited to different bacterial species representative of the 
corresponding sequence variation.  
Phylogenetic differences in rRNA provide the basis for selectivity of compounds affecting the 
ribosome. However, sequence polymorphisms in the mitochondrial small subunit rRNA, namely 
A1555G and less frequently C1494U, have been identified as primary genetic traits in non-
syndromic deafness. Both mutations locate to the A-site of mitochondrial 12S rRNA, a region 
essential for mRNA decoding. In addition to congenital deafness, the A1555G and C1494U 
mutations render affected individuals highly susceptible to aminoglycoside induced deafness. The 
high copy number of mitochondrial DNA in mitochondria and the vast number of mitochondria in a 
single cell have frustrated any attempt of genetic manipulation of mitochondrial rRNA in lower and 
higher eukaryotes. The absence of experimental models for diseases associated with 
mitochondrial rRNA polymorphisms has not only hampered insight into disease pathogenesis but 
also prevented the rational search for therapeutic interventions.  
In the thesis presented here, a derivative of the gram-positive Mycobacterium smegmatis 
rendered single rRNA operon allelic by gene-inactivation techniques was used for the 
experimental studies. Site-directed mutagenesis of the single chromosomal rRNA operon resulted 
in cells carrying homogenous populations of mutant ribosomes. Bacterial sequence 
polymorphisms were introduced representing the different bacterial clades. In addition, 
nucleotides in 16S rRNA helix 44 of M. smegmatis were replaced with those of wild-type and 
disease-associated mitochondrial versions resulting in hybrid ribosomes with a fully functional 
eukaryotic rRNA decoding site.  
1) The natural sequence variations in the ribosomal peptidyl transfer center of bacteria were 
found not to affect drug susceptibility, but to impact the resistance phenotype of the A2058G 
mutation, in particular to the ketolide telithromycin.  In contrast, natural sequence variations in the 
ribosomal A-site of bacteria affected both drug susceptibility and the resistance phenotype of the 
A1408G mutation. 
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2) The disease-associated sequence polymorphisms in mitochondrial rRNA, i.e. A1555G and 
C1494U, significantly reduced the accuracy of translation. Modelling the mitochondrial decoding 
site on available bacterial X-ray structures allowed to develop a structure-function hypothesis 
addressing the molecular mechanism of mutation-mediated misreading.  
3) Mitochondrial rRNA sequence polymorphisms A1555G and C1494U significantly increased 
drug binding and ribosomal susceptibility to aminoglycoside-induced inhibition of protein 
synthesis and aminoglycoside-induced mistranslation.  
The results presented in this thesis indicate that misreading of the genetic code is an important 
molecular mechanism in both mitochondrial rRNA polymorphism-associated deafness and in 
aminoglycoside-induced ototoxicity. Our data establish the hybrid ribosome approach as an 
excellent model to study the mechanisms of mutation- and aminoglycoside- mediated dysfunction 
of the mitochondrial ribosome and to address issues of species-specific drug action in bacteria.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 III 
II. Zusammenfassung 
 
Ribosomen sind riesige Ribonukleoproteinkomplexe, welche die Polymerisation von Aminosäuren 
katalysieren. Eine Fülle genetischer und biochemischer Untersuchungen weisen darauf hin, dass 
die rRNA eine entscheidende Rolle bei der Funktion des Ribosoms wie z. B. mRNA-Decodierung, 
tRNA-Bindung, Peptidyltransfer und Assoziation der Untereinheiten einnimmt. Das Ribosom ist 
das Angriffsziel für eine Vielzahl von Antibiotika, darunter Aminoglykoside, Makrolide, Ketolide, 
Oxazolidinone und Lincosamide. Diese Verbindungen greifen in verschiedene ribosomale 
Funktionen wie Peptidyltransfer, mRNA-Decodierung oder tRNA-Translokation ein. Ribosomale 
Antibiotika binden hauptsächlich an die rRNA, die innerhalb der jeweiligen Bindungstasche einen 
hohen Grad an phylogenetischer Sequenzkonservierung aufweist. Es ist unklar, ob die geringen 
Sequenzvariationen, die in der bakteriellen Wirkstoffbindestelle vorhanden sind, die 
Empfindlichkeit gegenüber Antibiotika bzw. die Entwicklung von Resistenzen beeinflussen. Bisher 
stiess man bei genetischen Manipulationen an methodische Grenzen, die es nicht erlaubten den 
Einfluss bakterieller rRNA-Sequenzvariationen auf die Empfindlichkeit gegenüber Antibiotika in 
isogenen Mutanten zu analysieren. Untersuchungen waren stattdessen auf verschiedene 
Bakterienarten begrenzt, die jeweils repräsentativ für die entsprechenden Sequenzvariationen 
sind. 
Phylogenetische Unterschiede in der rRNA bilden die Grundlage für die Selektivität von 
Antibiotika, die am Ribosom angreifen. Sequenzpolymorphismen in der rRNA der 
mitochondrialen kleinen Untereinheit, i.e. A1555G und seltener C1494U, wurden als primäre 
genetische Merkmale nicht-syndromischer Taubheit identifiziert. Beide Mutationen befinden sich 
in der A-Stelle der mitochondrialen 12S-rRNA, einer zur mRNA-Decodierung notwendigen 
Region. Zusätzlich zur angeborenen Taubheitsdisposition zeigen die A1555G- und C1494U-
Mutationen bei betroffenen Personen eine hohe Anfälligkeit für Aminoglykosid-induzierte 
Taubheit. Die Multiplizität mitochondrialer DNA-Kopien in Mitochondrien sowie die enorme Anzahl 
an Mitochondrien in einer einzigen Zelle haben jegliche Versuche zur genetischen Manipulation 
von mitochondrialer rRNA in niederen und höheren Eukaryonten vereitelt. Der Mangel an 
experimentellen Modellen für Krankheiten, die mit mitochondrialen rRNA-Polymorphismen 
assoziiert sind, hat nicht nur den Einblick in die Pathogenese dieser Erkrankungen erschwert, 
sondern auch die rationale Suche nach therapeutischen Interventionen behindert. 
In der vorliegenden Dissertation wurde für die experimentellen Untersuchungen ein Stamm des 
grampositiven Bakteriums Mycobacterium smegmatis verwendet, bei dem durch 
Geninaktivierungstechniken nur ein einzelnes rRNA-Operon exprimiert wird. Punktgenaue 
Mutagenese des einzelnen chromosomalen rRNA-Operons führte zu Zellen, die eine homogene 
Population mutierter Ribosomen aufweisen. Es wurden bakterielle Sequenzvariationen eingeführt, 
welche die verschiedenen Bakteriengruppen repräsentieren. Darüber hinaus wurden Nukleotide 
in Helix 44 der 16S-rRNA von M. smegmatis mit jenen von wildtyp- und krankheitsassoziierten 
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mitochondrialen Varianten ersetzt, woraus hybride Ribosomen mit einer vollständig 
funktionsfähigen eukaryontischen rRNA-Decodierungsstelle resultierten.  
1) Es stellte sich heraus, dass die natürlichen Sequenzvariationen im ribosomalen 
Peptidyltransferasezentrum von Bakterien keine Auswirkung auf die Empfindlichkeit gegenüber 
Antibiotika haben, aber den Resistenzphänotyp der A2058G-Mutation, insbesondere gegenüber 
dem Ketolid Telithromycin, beeinflussen. Dagegen wirkten sich natürliche Sequenzvariationen in 
der ribosomalen A-Stelle von Bakterien sowohl auf die Empfindlichkeit gegenüber 
Aminoglycosiden als auch auf den Resistenzphänotyp der A1408G-Mutation aus. 
2) Die krankheitsassoziierten Sequenzpolymorphismen mitochondrialer rRNA, d. h. A1555G und 
C1494U, führten zu einer signifikanten Reduktion der Translationsgenauigkeit. Die Modellierung 
der mitochondrialen Decodierungsstelle anhand vorliegender bakterieller Röntgenstrukturen 
ermöglichte die Entwicklung einer Struktur-Funktionshypothese, die den molekularen 
Mechanismus von mutationsvermittelten Lesefehlern beschreibt. 
3) Die Sequenzpolymorphismen A1555G und C1494U in mitochondrialer rRNA führten zu einer 
signifikanten Zunahme der Bindung von Aminoglycosid-Antibiotika. Sie erhöhen die ribosomale 
Empfindlichkeit gegenüber Aminoglykosid-induzierter Hemmung der Proteinsynthese und 
Aminoglykosid-induzierten Translationsfehlern. 
Die in dieser Dissertation präsentierten Ergebnisse deuten darauf hin, dass Fehler beim Ablesen 
des genetischen Codes einen wichtigen Mechanismus sowohl bei Taubheit, welche mit 
Polymorphismen in mitochondrialer rRNA assoziiert ist, als auch bei Aminoglykosid-induzierter 
Ototoxizität darstellt. Unsere Daten etablieren den Hybridribosomenansatz als ein 
ausgezeichnetes Modell zur Analyse Mutations- und Aminoglykosid-vermittelter Fehlfunktion des 
mitochondrialen Ribosoms und zur Untersuchung von Aspekten artspezifischer 
Antibiotikaempfindlichkeit in Bakterien. 
 
 
 
1. Introduction 
1.1 Ribosome: Composition 
Ribosomes, the universal riboprotein assemblies, are the nanomachines which translate the 
genetic code into proteins. These organelles, of a molecular weight of about 2.5 MDa in bacteria 
and up to 4 MDa in higher organisms, are composed of many different proteins and huge RNA 
chains accounting for two-thirds of the mass. All ribosomes are constituted of two unequal 
subunits, which associate during the initiation step of protein biosynthesis. In prokaryotes, the 
small subunit, denoted as 30S, contains an RNA chain (16S) of about 1500 nucleotides and 20-
21 different proteins, whereas the large subunit (called 50S in prokaryotes) has two RNA chains 
(23S and 5S RNA) of about 3000 nucleotides in total, and 31–35 different proteins (Table 1). 
 
 
Table1: Ribosomal composition from the 3 domains of life and mitochondria (42). 
 
1.2 Ribosome: Mechanism of translation 
Translation is a multistep process which involves both the ribosomal subunits and a host of 
translation factors (Figure 1) (46). The mRNA carries the genetic information that is translated by 
the ribosome and tRNAs bring the amino acids to the ribosome. The ribosome contains three 
sites for hosting its tRNA substrates, each residing on both the subunits. The A-site hosts 
aminoacyl-tRNA (aa-tRNA) molecules, while the P-site hosts the growing peptidyl-tRNA (pept-
tRNA). E denotes the site of the exiting tRNA. The decoding center resides on the small subunit, 
hence the mRNA and the tRNA anticodon loops are attached to it, whereas the catalytic site of 
the ribosome, the peptidyl transferase center (PTC), resides on the large subunit. During the 
formation of the peptide bond, nucleophilic attack of the amino group of the aa-tRNA in the A site 
on the carbonyl carbon of pept-tRNA produces a pept-tRNA that is elongated by one amino acid 
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residue and the deacylated tRNA moves into the E site and then exits the ribosome (34). The 
pept-tRNA is then translocated into the P-site to facilitate another round of elongation. The 
decoding and formation of the peptide bonds occur in an iterative manner, resulting in a 
polypeptide chain with a sequence dictated by the mRNA sequence. All these stages occur 
usually with the expenditure of energy in the form of guanosine triphosphate (GTP) (53). 
 
 
Figure 1: The different steps of bacterial translation (53) 
 
Ribosome function has been studied for many decades by biochemical and genetic approaches. 
These studies have shown that ribosomal RNA (rRNA), the main component of ribosomes, plays 
a crucial role in essentially all aspects of translation (32). Recent X-ray crystallographic and cryo-
EM studies of prokaryotic ribosomes have provided a wealth of structural information about 
various steps in translation.  
tRNA selection is a multistep process that occurs when the anticodon of an aminoacyl-tRNA base 
pairs with a mRNA codon located in the ribosomal A site. Crystallographic studies have shown 
that three universally conserved nucleotides of Escherichia coli 16S rRNA: G530 from helix 18 
and A1492 and A1493 from helix 44 probe the codon-anticodon helix to ensure the accuracy of 
the codon-anticodon match during translation elongation. When a cognate codon-anticodon 
interaction occurs, G530 transitions from a syn to an anti conformation, while A1492 and A1493 
flip out into the minor groove of the codon-anticodon helix (35). These conformational changes 
allow the decoding site to monitor the proper codon-anticodon interaction by hydrogen bonding to 
2′ hydroxyl groups on either side of the cognate codon-anticodon helix, providing a sensitive test 
of codon-anticodon pairing.  
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Ribosomes catalyze peptide bond formation between aa-tRNA bound to the A site of the 
ribosome and pept-tRNA at the P site. The active site for peptide bond formation, the PTC, is 
located on the large (50S) ribosomal subunit. High-resolution crystal structures of the 50S subunit 
have revealed that the PTC is composed of 23S rRNA (domain V), with no protein within 15 Å of 
the active site (3). This implies that peptide bond formation is catalyzed by RNA and, thus, the 
ribosome is a ribozyme. Prior to the PT reaction, the tRNA substrates have to bind their 
respective sites on the ribosome. The conserved 23S rRNA bases A2451, U2506, U2585, C2452, 
and A2602 are located at the core of the PTC. The acceptor arms of the A and P site tRNAs are 
located in a cleft of the 50S interface side. Their universally conserved CCA ends are oriented 
and held in place by interactions with residues of 23S rRNA near the active site.  The peptide 
bond is formed as a result of nucleophilic attack by the α-amino group of aa-tRNA on the ester 
carbonyl group of pept-tRNA (4).  
Following peptidyl transfer, the P-site tRNA is deacylated and the A-site tRNA has a peptide 
chain that has one additional residue. To prepare the ribosome for a new round of peptide chain 
elongation, the tRNAs have to move i.e. the deacylated tRNA needs to be moved from the P-site 
to the E-site and eventually ejected from the ribosome, while the pept-tRNA has to move from the 
A-site to the P-site. Moreover, this movement has to be precise, and the reading frame on mRNA 
has to be preserved. It was proposed that translocation would involve a relative movement of the 
two subunits, and could occur in separate steps relative to the 50S and 30S subunits in the 
presence of Elongation Factor G and GTP (17).  
The growing polypeptide chain is threaded through a polypeptide exit tunnel which is below the 
PTC and spans the large ribosomal subunit. It is lined primarily by rRNA but several ribosomal 
proteins also reach its wall. Recent biochemical findings show that the ribosomal exit tunnel is a 
dynamic functional entity with the ability to take part in elongation arrest, discrimination and 
possibly also protein folding (33).  
 
1.3 Ribosome: A drug target 
A great variety of natural, semisynthetic or synthetic antibiotics inhibit the growth of bacteria by 
binding to their ribosomes and interfering with translation (42, 62). For decades, protein synthesis 
inhibitors have been among the most successful, clinically useful antibiotics (66). The ribosomes 
are ribozymes because the most important functions are carried out by the rRNA. Thus, the 
decoding site, the PTC and the protein exit tunnel are formed by rRNAs, and most ribosomal 
antibiotics interact primarily with these rRNAs (6, 65, 66). More recent crystallographic studies of 
ribosomal subunits complexed with a variety of antibiotics presented an extended panel of 
fascinating, detailed understanding of the ribosome–drug interactions at atomic resolution (Table 
2). 
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 Drugs targeting the small (30S) ribosomal subunit 
Antibiotic class Mode of action 
Aminoglycosides Bind to the A-site and induce misreading of the genetic code 
Tetracyclines 
Viomycin, 
Capreomycin  
Block binding of tRNA to A-site  
Drugs targeting the large (50S) ribosomal subunit 
Antibiotic class Mode of action 
Macrolides and 
ketolides 
Bind to the polypeptide exit tunnel and prevent elongation 
of nascent peptide 
Streptogamins  
Lincosamides 
Pleuromutilins 
Block peptide bond formation 
 
Table 2: Antibiotics targeting the bacterial ribosome.  
  
1.3.1 Aminoglycosides 
In the small ribosomal subunit, the best-studied site of drug action is the decoding centre, which 
is targeted by aminoglycosides (26). Common aminoglycoside antibiotics share a universal two-
ring structure of neamine that includes the 2-deoxystreptamine moiety (ring II). Depending on the 
type of ring II substitution (4,5 or 4,6), the drugs fall into neomycin/paromomycin or 
kanamycin/gentamicin families respectively (Figure 2). 
 
 
Figure 2: Chemical structures of 2-deoxystreptamine (ring II)-containing aminoglycosides. The 
2-DOS scaffold is highlighted in blue. 
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The decoding site comprises a segment of an extended rRNA helix 44 that resides on the 
interface surface of the small subunit (Figure 3a) (35). Both structural and functional studies 
indicate that the degree of aminoglycoside binding to the prokaryotic decoding site is greatly 
influenced by two nonconserved nucleotides, A1408 and G1491 (E. coli numbering used 
throughout) (39, 40). A1408 makes hydrogen bonds with the group at the 6′ position of ring I of 
aminoglycosides to form a pseudo base-pair interaction (61). G1491 provides a stacking 
interaction with ring I to stabilize the pseudo base-pair interaction between ring I and A1408 
(Figure 3b) (39). The universal interactions of rings I and II of the neamine moiety of 
aminoglycosides with the decoding centre are supplemented by opportunistic (‘fuzzy’) interactions 
that drug-specific rings III and IV of aminoglycosides establish with helix 44 of 16S rRNA (26-28). 
These fuzzy contacts fine tune placement of the drug within its RNA target and contribute to 
consequence of aminoglycoside resistance mutations. 
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Figure 3: (a) Secondary structure of helix 44 of the 16S rRNA. (b) View of the three-dimensional 
structure of the A-site complexed with 4,5- and 4,6-disubstituted 2-deoxystreptamines: the 
common neamine core is denoted in yellow; ring III of the 4,6-compounds (tobramycin) is 
denoted in red; and rings III and IV of the 4,5-compounds (paromomycin) are denoted in blue. 
Key nucleotides (E. coli numbering) of the binding site are given in bold (7). 
 
Ribosome crystallography provided a clear view of the mechanism of action of aminoglycoside 
drugs that act at the decoding centre. The neamine core-based aminoglycoside drugs affect the 
ribosome accuracy at the initial step of aminoacyl-tRNA selection (11). During decoding, the 
ribosome monitors the codon-anticodon interaction to ensure that the aa-tRNA is cognate to the 
mRNA. This function involves two universally conserved nucleotides of the 16S rRNA, A1492 and 
A1493, which flip-out of helix 44 in the 30S subunit to monitor the minor groove of the codon-
anticodon duplex (Figure 4). Presumably the energy required to flip-out A1492 and A1493 during 
decoding is compensated for by additional A-minor interactions established with the codon-
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anticodon duplex, thus stabilizing this “flipped out” conformation (35). This switch occurs during 
mRNA decoding when these two adenines monitor the accuracy of codon-anticodon base pairing 
at the first and second anticodon positions. Flipping out of the adenines 1492/1493 during 
decoding signals the establishment of an accurate codon-anticodon pairing.  In the presence of 
near-cognate tRNA these compensatory interactions are presumably insufficient to stabilize the 
flipped out A1492 and A1493 and thus the near-cognate tRNA dissociates. Binding of the 
universal aminoglycoside rings I and II to the decoding centre changes the orientation of two 
universally conserved adenine residues at positions 1492 and 1493 of 16S rRNA (Figure 4). 
Reorientation of A1492/A1493 induced by aminoglycosides explains the miscoding effect of these 
drugs: in the presence of a bound aminoglycoside, the decoding centre issues an approval signal, 
even on the binding of a near-cognate tRNA, thereby increasing the frequency of amino acid 
misincorporation (36). 
 
Figure 4: Nucleotides A1492 and A1493 are shown in the conformation that they adopt after 
having flipped out of the 16S rRNA helix 44 to interact with an mRNA codon (magenta) and its 
cognate tRNA anticodon (green) at the ribosomal aminoacyl site. The conformational changes 
induced at these nucleotides and at G530 are indicated by the arrows. The aminoglycoside 
antibiotics paromomycin (red) and geneticin (blue) bind within helix 44 as shown, and induce a 
similar, but not identical, conformational shift in A1492 and A1493. Adapted from (42). 
 
 
1.3.2 Macrolides and ketolides 
Amongst the many antibiotics that target the large (50S) ribosomal subunit the macrolides are the 
most well studied. Macrolides are polyketide compounds synthesized by the actinomycetes and 
can be classified structurally into groups in a variety of different ways easiest being on the basis 
of the size of their macrolactone ring, which can vary significantly from as small as 8-12 
membered (methylmycin) to as large as 20 (rapamycin)(47). However, the most commonly used 
macrolides consist of a 14- to 16-atom lactone ring decorated with one or several sugars and 
side-chains (Figure 5). The emergence of bacterial strains resistant to macrolides has resulted in  
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Figure 5: Structures of commonly used macrolides: 14-membered erythromycin and 
clarithromycin, 15-membered azithromycin, 16-membered spiramycin. tylosin and josamycin 
and the ketolide telithromycin. 
 
the introduction of ketolides. Ketolides are semi-synthetic derivatives of macrolides and possess 
additional side-chains and modification such as the alkyl-aryl side chain of telithromycin (10). 
These drugs bind at the upper segment of the nascent peptide exit tunnel in the large ribosomal 
subunit near the peptidyl transferase centre (52, 59). 
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Crystallographic studies of macrolides complexed to the large ribosomal subunit showed a 
conserved interaction of the macrolide core with the ribosome. The lactone ring binds to the wall 
of the tunnel primarily because of the hydrophobic interactions that involve, among others, 
residues A2058 and A2059 (Figure 6) (23). 
 
 
Figure 6: Secondary structure of domain V of 23S rRNA. rRNA residues are numbered 
according to their homologous positions in E. coli 23S rRNA. 
 
The C5-linked sugars project toward the PTC. Their hydrophobic and hydrogen bonding 
interactions with the 23S rRNA residues A2058 and A2059 contribute significantly to the binding 
energy of the drug (Figure 7). Contacts of the macrolactone ring and the C5-linked sugar residues  
 
 
 
a b
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Binding of macrolides to the large ribosomal subunit. (a) Macrolide binding pocket 
located near the peptidyl transferase center. aa-tRNA (brown), pept-tRNA (black) and ribosomal 
proteins L4 and L22 (green), lining the polypeptide exit tunnel (blue) are indicated (31). (b) A 
view into the macrolide binding pocket. The positions of erythromycin (red) and telithromycin 
(blue) are superposed (38). 
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involve exclusively rRNA and account for a significant portion of the drugs’ binding energy. Other 
sugar residues found in some of the macrolide antibiotics make additional contacts with the 
ribosome target. For example, the C14-linked mycinose residue of tylosin protrudes down the 
tunnel, away from the PTC and interacts with the loop of helix 35 in domain II of 23S rRNA and 
with ribosomal protein L22 (37). The extended alkyl–aryl side-chain of clinically relevant ketolides 
bound to the bacterial ribosome appears to project in the same direction and probably makes 
similar contacts (5). These latter drug-specific contacts may contribute significantly to the drug 
affinity for its ribosomal binding site (24). Bound to the bacterial (Deinococcus radiodurans) large 
subunit (D50S), the sidechain of telithromycin penetrates deeper into the tunnel forming stacking 
interactions with A752 (5), consistent with the protection of A752 from chemical modification (13). 
Interestingly, in contrast to the similar positions of the lactone rings, the conformation of the 
telithromycin side-chain bound to the archaeal (Haloarcula marismortui) large subunit (H50S) is 
dramatically different. These structural differences that modulate the mode of binding of the drug 
to the ribosome probably stem from the low sequence conservation within this region. More 
generally, this suggests that antibiotic binding to ribosomes of different organisms/strains may 
utilize distinct binding modes, which has important implications for structure-based drug design 
(63). Such variation in binding modes is also illustrated by the binding of two molecules of 
azithromycin to D. radiodurans 50S ribosomes (51), but only one molecule to H. marismortui 
ribosomes (23).  
Significant progress has also been achieved in understanding the mode of action of macrolides. 
The binding of macrolides in the exit tunnel close to the peptidyl transferase centre inhibits 
translation by blocking progression of the nascent peptide through the exit tunnel (52). The 
distance between the PTC, where formation of peptide bonds takes place and the macrolide-
binding site is only 10 Å. A three to four amino acid long nascent peptide should reach the bound 
antibiotic. Yet, accurate measurements showed that pept-tRNA dropped-off of the erythromycin-
bound ribosome carried nascent peptides which were six to eight amino acids long (55). 
Ribosomes with bound telithromycin could polymerize even longer peptides 9–10 amino acid 
residues long before the dissociation of pept-tRNA (55). The effect of macrolides in blocking 
egression of the nascent polypeptide chain may not be uniform for all mRNAs, but rather be 
dependent on the nascent polypeptide chain being synthesized (31). Indeed, macrolides with 
extensive side-chains extending from the C5 position even inhibit peptidyl transferase activity to 
varying extents, such as carbomycin (100% inhibition), spiramycin (85%) and tylosin (~60%), 
whereas those with shorter side-chains, such as erythromycin, do not (43).  
 
1.4 Natural rRNA sequence variations and drug susceptibility  
Protein synthesis is a key and universal process, and the high evolutionary conservation of 
functional sites within rRNAs, targeted by ribosomal drugs, implies limitations with respect to 
selectivity and toxicity (8). Still, comparisons of rRNA sequences have shown subtle differences 
in these locations, despite their conservation, and these minute differences might govern drug 
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selectivity (1). Thus, a single nucleotide can determine the selectivity of drugs affecting protein 
synthesis. However, a multitude of different nucleotides located within the rRNA participate in the 
binding of a drug to its target region; correspondingly, several different nucleotide substitutions 
can be associated with drug selectivity (6, 8). As a result, the same antibiotic might bind in 
different modes to slightly different ribosomal pockets, and this can be influenced not only by the 
often-conserved nucleotides of a functional site targeted by an antibiotic but also by the less-
conserved peripheral rRNA residues (56).  
Nucleotides of 16S rRNA helices 18, 34 and 44 form the A-site and are highly conserved, 
reflecting their importance in mRNA decoding (21). While aminoglycosides form a number of 
hydrogen bonds with different nucleotides in helix 44, their interactions with rRNA residues 1408, 
1409 and 1491 appear to be most critical for drug binding (27, 28, 39). Minor sequence variations 
occur within the aminoglycoside-binding pocket of helix 44 involving 16S-rRNA base-pair 1409-
1491 (21). The majority of eubacteria are characterized by a 1409 pyrimidine-1491 purine (C-G) 
interaction whereas propionibacteria carry a 1409 purine-1491 pyrimidine (A-U) base pair (Figure 
8). 16S rRNA residue 1408 is an adenine in all bacteria. Among all A-site mutations that confer 
aminoglycoside resistance, the 1408 adenine to guanine mutation is the predominant alteration 
(44, 48). It is also believed to function as the main specificity determinant of aminoglycosides, 
because higher eukaryotes carry a guanine at this position (8). 
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Figure 8: Secondary structure of 16S rRNA helix 44 decoding site. rRNA residues are 
numbered according to their homologous positions in E. coli 16S rRNA. Phylogenetic 
sequence variations analyzed in this study are represented in blue, the adenine at position 
1408 in red. 
 
Most rRNA nucleotides in the inner peptidyl-transferase region of the large ribosomal subunit are 
phylogenetically conserved (22). The macrolide/ketolide family of antibiotics binds to a 
hydrophobic cleft formed by residues 2058, 2059 and 2611 in domain V of 23S rRNA (24). The 
adenines at 23S rRNA positions 2058 and 2059 are phylogenetically conserved in bacteria and 
play an important role in binding, selectivity and resistance towards macrolides/ketolides (1, 41, 
49) (Figure 9). Ribosomal susceptibility to macrolides and ketolides is also determined by proper 
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Watson-Crick base pairing between nucleotides at positions 2057 and 2611 (12), which are 
typically G-C in proteobacteria and A-U in mycobacteria.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Secondary structure of domain V of the 23S rRNA. rRNA residues are numbered 
according to their homologous positions in E. coli 23S rRNA. Base pair 2057-2611 is 
represented in blue and the adenine at position 2058 in red. 
 
1.5 Mitochondrial organization and translation 
Mitochondria are intracellular double membrane-bound structures found ubiquitously in 
eukaryotes and are essential for survival. Their primary function is to support aerobic respiration 
and to provide energy substrates (such as ATP) for intracellular metabolic pathways. 
Mitochondria have also been shown to play an important role in cell signalling, particularly in 
signalling for apoptotic cell death. Mitochondria host several metabolic pathways, including the 
Krebs cycle, β-oxidation, and lipid and cholesterol synthesis. Given their fundamental role in the 
human body, defects of mitochondrial function can have disastrous consequences.  
Mitochondria are the only location of extra-chromosomal DNA within the vertebrate cell, and they 
are under the dual genetic control of both nuclear DNA and the mitochondrial genome. Human 
mtDNA is extremely compact and contains no non-coding sequences. The mitochondrial genome 
consists of a multicopy, circular dsDNA molecule (16.6 kb in humans), which encodes 13 
essential polypeptides of the OXPHOS system and the necessary RNA machinery (2 rRNAs and 
22 tRNAs) for their translation within the organelle. The remaining protein subunits that make up 
the respiratory-chain complexes, together with those required for mtDNA maintenance, are 
nuclear-encoded, synthesized on cytoplasmic ribosomes, and are specifically targeted and sorted 
to their correct location within the organelle. MtDNA is highly polymorphic, with several 
differences in sequence between individuals from the same ethnic group and more between 
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those in different groups. MtDNA haplotypes are based upon specific patterns of polymorphisms 
and seem to influence the ageing process, susceptibility to some diseases, and the expression of 
some mtDNA mutations. All 13 proteins encoded by human mtDNA are subunits of the 
respiratory chain and OXPHOS (Figure 10).   
 
 
 
Figure 10: Mitochondrial respiratory chain and oxidative phosphorylation system. Each 
hexagon represents a polypeptide product of a single gene (50). 
 
Mitochondrial genetics is different from Mendelian genetics in almost every aspect, from the 
uniparental inheritance of disease mutations, to the presence of many copies of the genome 
within a single cell and the basic mechanisms that underlie replication and control of transcription. 
The polyploid nature of the mitochondrial genome up to several thousand copies per cell gives 
rise to an important feature of mitochondrial genetics, homoplasmy and heteroplasmy. In simple 
terms, homoplasmy is when all copies of the mitochondrial genome are identical; heteroplasmy is 
when there is a mixture of two or more mitochondrial genotypes. Some mutations affect all copies 
of the mitochondrial genome (homoplasmic mutation), whereas others are only present in some 
copies of the mitochondrial genome (heteroplasmic mutation). The differences between the two 
genetic systems in human cells are probably a relic of evolution, but lead to some fascinating 
biology that dictates the functional consequences of mtDNA mutations.  
The mRNAs for the 13 mtDNA-encoded OXPHOS proteins are translated on mitochondrial 
ribosomes. Human 55S mitoribosomes contain two subunits, i.e. 28S and 39S. The small 
ribosomal subunit comprises 12S rRNA and 28 proteins, and the large subunit contains the 16S 
rRNA and 48 proteins. Surprisingly, the rRNA:protein ratio in mitoribosomes is different (1:2) to 
that in cytosolic and bacterial ribosomes (2:1). Mitoribosomes contain a higher protein content 
and lack several of the major rRNA structures of bacterial ribosomes.  
 
1.6 Diseases caused by mitochondrial dysfunction 
Mitochondrial defects can be inherited or acquired. Inherited mtDNA mutations are responsible 
for many clinical abnormalities, including various forms of neuropathy, myopathy, cardiomyopathy, 
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retinal degeneration, diabetes mellitus and sensorineural hearing loss (SNHL) (18). In addition, 
there is increasing evidence that acquired mtDNA mutations are involved in aging and age-
related diseases such as cancer, and diabetes (54). Healthy individuals appear to have only a 
single mtDNA genotype (i.e., homoplasmic), but, in many mitochondrial disease states, there are 
mixed mtDNA genotypes (i.e., heteroplasmic). The amount of heteroplasmy varies from tissue to 
tissue, and for cells within a tissue. Inherited deafness-associated mtDNA mutations usually 
occur in the genes encoding proteins or genes for components of the protein-synthesizing 
apparatus, i.e. rRNAs and tRNAs.  
 
1.7 Mitochondrial 12S rRNA mutations and sensorineural hearing loss 
Mutations in mitochondrial DNA (mtDNA) have been found to be associated with both 
aminoglycoside-induced and non-syndromic deafness (16, 60). Mitochondrial rRNA mutations 
associated with SNHL are only found in the 12S rRNA gene, i.e. A1555G (14, 45), C1494T (67), 
T1095C (57, 58), A827G (64), and 961 mutations (2). In particular, the A1555G mutation has 
been found to be responsible for nonsyndromic deafness in many families of different ethnic 
backgrounds (15). In the absence of exposure to aminoglycosides, the A1555G mutation 
produces a clinical phenotype that varies considerably among family members, ranging from 
severe congenital deafness to moderate progressive hearing loss of later onset to completely 
normal hearing (14, 30). Affected persons are homoplasmic for the mutation, a condition that 
appears to be more frequent in certain populations. Functional characterization in an Arab-Israeli 
family demonstrated that more severe biochemical defects were observed in mutant 
lymphoblastoid cell lines derived from symptomatic individuals than in cell lines derived from 
asymptomatic individuals (19). However, under a constant nuclear background, a nearly identical 
degree of mitochondrial dysfunction was observed in cybrid cell lines derived from symptomatic 
or asymptomatic individuals from this family (20). These genetic and biochemical data strongly 
point out that the A1555G mutation is a primary factor underlying the development of deafness 
and other factors play a role in modulating the phenotypic expression of the hearing loss 
associated with the A1555G mutation. Clinical, genetic, and biochemical data have shown that 
the aminoglycoside antibiotics (45), mitochondrial haplotypes (30), and nuclear modifier genes 
(20) are three major modulators for the phenotypic expression of the deafness-associated 12S 
rRNA mutations. Although hearing loss caused by A1555G mutation is usually nonsyndromic, 
additional symptoms including Parkinson disease and cardiomyopathy have been reported on 
occasions (60).   
 
1.8 Aminoglycosides and ototoxicity 
Mitochondrial ribosomes share more similarities with bacterial ribosomes than do cytosolic 
ribosomes (29). Therefore, it is reasonable to suggest that the ototoxic site of action of 
aminoglycoside antibiotics involves the mitochondrial ribosome. There are two forms of 
aminoglycoside-induced deafness: sporadic dose-dependent and inherited idiosyncratic. The fact 
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that aminoglycoside hypersensitivity is often maternally transmitted suggests that mtDNA 
mutation(s) are involved in aminoglycoside ototoxicity (16). Sequence analyses of the 
mitochondrial genome in patients with aminoglycoside ototoxicity have led to the identification of 
ototoxic mtDNA mutations in the 12S rRNA gene: A1555G, and C1494T mutations (Figure 11). 
These two mutation account for ototoxicity in 17-33% of the cases (15).  
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Figure 11: Secondary structure of wild-type helix44 nucleotides of human mitochondrial 12S 
rRNA in comparison to disease-associated mutations. 
 
The A1555G mutation has been found in a number of families and sporadic patients with 
aminoglycoside-induced severe hearing loss (14).  The A1555G mutation is located at a highly 
conserved region of 12S rRNA that is an essential part of the decoding site of the small ribosomal 
subunit and important for the action of aminoglycosides. In humans, the nucleotide at position 
1555 in the 12S rRNA gene in wild-type cells is A, and, when A is mutated to G, it would pair with 
C at position 1494 (18). In addition to clinical variability in the phenotypic expression of 
aminoglycoside ototoxicity, there is also some evidence that the ototoxicity in patients is restricted 
to the cochlea and the vestibular systems remain unaffected. Patients with hearing loss after 
treatment with streptomycin did not reveal any vestibular abnormality (9). This tissue specificity 
maybe because aminoglycosides are concentrated within cochlear cells and remain there for 
prolonged periods (25). 
Another mitochondrial mutation predisposing to aminoglycoside ototoxicity was identified in a 
large Chinese pedigree with maternally-inherited hearing loss (67). Family members in the 
maternal line demonstrated hearing ranging from severe hearing loss to normal hearing, and had 
subsequent severe to profound hearing loss when exposed to aminoglycosides. Mutational 
analysis of the mitochondrial 12S rRNA revealed a homoplasmic C to U transition at position 
1494. Interestingly this mutation leads to a nucleotide pairing U1494-A1555 in the penultimate 
loop of the 12S rRNA in the conserved aminoglycoside binding region very similar to the base 
pairing generated by the A1555G mutation C1494-G1555.  In lymphoblastoid cell lines derived 
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from individuals carrying the C1494T mutation, exposure to a high concentration of paromomycin 
or neomycin caused a variable but significant increase in doubling time, as well as a significant 
decrease in the rate of total oxygen consumption as compared with controls (68). These results 
suggest that the C1494T mutation is a primary factor related to hearing loss and that the nuclear 
genetic background may play a role in the phenotypic expression associated with this mutation. 
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Despite the fact that important genetic diseases are caused by
mutant mitochondrial ribosomes, the molecular mechanisms by
which such ribosomes result in a clinical phenotype remain largely
unknown. The absence of experimental models for mitochondrial
diseases has also prevented the rational search for therapeutic
interventions. Here, we report on the construction of bacterial
hybrid ribosomes that contain various versions of the mitochon-
drial decoding region of ribosomal RNA. We show that the patho-
genic mutations A1555G and C1494T decrease the accuracy of
translation and render the ribosomal decoding site hypersuscep-
tible to aminoglycoside antibiotics. This finding suggests misread-
ing of the genetic code as an important molecular mechanism in
disease pathogenesis.
decoding  mitochondria  mutant rRNA  ribosomes  disease
Genes encoded by mitochondrial DNA (mtDNA) have beenlinked to a variety of diseases (1, 2). One of the most
common phenotypes associated with mitochondrial diseases is
sensorineural deafness; corresponding mitochondrial mutations
localize to tRNA and rRNA genes (2, 3). In particular, the
single-nucleotide alteration A1555G has been identified as a
major source of nonsyndromic deafness (4) and has since been
found in patients from all ethnic backgrounds and geographic
origins. More recently, a C1494T point mutation has been
associated with nonsyndromic deafness (5); C1494 forms a
noncanonical RNA base pair with the adenine encoded by 12S
rRNA position 1555 (Fig. 1). Both mutations locate to the
penultimate helix of mitochondrial 12S rRNA, which is a com-
ponent of the aminoacyl-tRNA acceptor site (A site), a region
of the small subunit rRNA essential for mRNA decoding (6). In
bacteria, the A site is a target for aminoglycoside antibiotics,
compounds that are compromised by a substantial degree of
ototoxicity (7). Presumably, drug toxicity relates, at least in part,
to limited selectivity between the bacterial and themitochondrial
A site and to the mechanism of drug action, i.e., miscoding (8).
Interestingly, and in addition to congenital deafness, the
A1555G and the C1494T mutations render affected individuals
highly susceptible to aminoglycoside-induced deafness (4, 5).
By itself, the A1555G mutation produces a clinical phenotype
that may range from severe congenital deafness through mod-
erate progressive hearing loss of later onset to normal hearing
(3). Evidence has accumulated that the nuclear background
plays an important role in the phenotypic manifestation of
nonsyndromic deafness associated with mitochondrial rRNA
mutations (9, 10), although cochlear alterations have been
demonstrated to be present in symptomatic and asymptomatic
carriers of the A1555G mutation (11). Biochemical investiga-
tions of deafness-associated mtDNAmutations have so far relied
on the characterization of transmitochondrial cell lines, con-
structed by transferring mitochondria from cell lines of affected
patients into the human cell line p°206 lacking mtDNA (9, 10).
Nonetheless, the mechanistic link between mitochondrial mu-
tation and disease has remained largely elusive and is still to be
established, mainly because of the absence of suitable experi-
mental models. Mice models for mitochondrial diseases have
been limited to nuclear-encoded proteins, as the technical
hurdles to create animal models of pathogenic mtDNA muta-
tions remain formidable (12). In the absence of experimental
models for ribosomes of higher eukaryotes, a spontaneous yeast
mutant with a mitochondrial rRNA C1477-to-G alteration con-
ferring resistance to paromomycin has been used as a model for
the humanmitochondrial A1555G deafness mutation (13). How-
ever, this yeast mutant does not show a discernible phenotype in
translation (13, 14), and yeast mitochondrial rRNA position 1477
corresponds to human mitochondrial rRNA position 1493 rather
than 1494 [see supporting information (SI) Fig. 5 and compare
with Fig. 1]. We wanted to test whether the prokaryotic A site
in the bacterial ribosome can be modified so as to serve as a
model for the A site of mitochondrial ribosomes, as it would
allow the study of the pathogenesis of mitochondrial rRNA-
associated deafness mutations.
Results and Discussion
Much of the small subunit A-site rRNA, i.e., the corresponding
regions of helices 18, 34, and 44 of 16S rRNA, is highly conserved
in structure and nucleotide sequence between bacteria and
mitochondria (15). Toward this end, we constructed bacterial
hybrid ribosomes comprising the mitochondrial homologue of
bacterial helix 44 (H44) of the 16S RNA decoding region by
using a single-rRNA allelic derivative of Mycobacterium smeg-
matis and a previously describedmutagenesis strategy (16). After
several attempts to transfer parts of the mitochondrial H44 into
M. smegmatis ribosomes, we were eventually able to generate
recombinant strains with homogenous populations of hybrid
ribosomes in which the central 34-nt part of rRNA helix 44 is
identical to that of the human mitochondrial decoding site (Fig.
1). We next constructed recombinants where the bacterial H44
is replaced with mitochondrial deafness alleles corresponding to
mtDNA mutations A1555G and C1494T. The resulting mutant
mitochondrial hybrid ribosomes differ from the wild-type
mitochondrial hybrid only in nucleotide position 1555 or 1494,
corresponding to Escherichia coli positions 1490 and 1410
(Fig. 1).
Because both mitochondrial rRNA mutations localize within
the ribosomal decoding site, we hypothesized that they may
affect the rate or accuracy of protein synthesis. For a biochemical
analysis of the deafness mutations and their effect on mRNA
decoding and polypeptide synthesis, 70S hybrid ribosomes were
purified and studied in a cell-free translation assay with an
AUG(UUU)12 mRNA as template. This template allows the
determination of both the rate of amino acid incorporation and
the frequency of codon misreading; codon ambiguity between
leucine and phenylalanine is at the third codon position, UUU/
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UUC for phenylalanine versus UUA/UUG for leucine. This
assay with its artificial mRNA has an intrinsically high error rate
(17) and should thus provide a sensitive measure for studying
misreading in wild-type compared with mitochondrial hybrid
ribosomes. Translation of AUG(UUU)12 into oligopeptides
composed of the cognate amino acid phenylalanine was com-
parable in hybrid ribosomes carrying either the mitochondrial
wild-type or the A1555G- or C1494U-mutated decoding site
(Fig. 2A and Table 1). In contrast, the accuracy of mRNA
translation was significantly reduced in the hybrid ribosomes
carrying a deafness mutation. Misincorporation of the near-
cognate amino acid leucine by AUG(UUU)12-directed synthesis
was increased 4-fold in the C1494U mutant as compared with
wild-type mitochondrial and bacterial ribosomes (Fig. 2A and
Table 1). Hybrid ribosomes carrying the A1555G mutation
showed a 7-fold increase in leucine misincorporation relative to
the wild-type mitochondrial hybrid. In absolute numbers, the
A1555G and C1494Umutant A sites accommodated two leucine
tRNAs per 7 and 15 phenylalanine tRNAs, respectively. Thus,
although both deafness mutations result in substantial codon
misreading, the error frequency is more pronounced in the
A1555G mutant.
Fig. 1. Secondary-structure comparison of decoding-site rRNA sequences in the small ribosomal subunit. (A) Decoding region of 16S rRNA helix 44 in wild-type
ribosomes of M. smegmatis; rRNA nucleotides are numbered according to the bacterial nomenclature, i.e., to homologous E. coli 16S rRNA positions. (B)
Homologous 12S rRNA sequence in human mitochondrial ribosomes; rRNA residues are numbered according to the mitochondrial nomenclature: mtDNA 1494,
1555, and 1556 correspond to E. coli 16S rRNA 1410, 1490, and 1491. (C–E) Decoding site rRNA of human–bacterial hybrid ribosomes. The transplanted helix is
boxed, and nucleotide positions depicted in blue represent residues that are specific for human mitochondrial rRNA. Mutations that are associated with
congenital deafness, mtDNA position 1555A to G (D), and 1494C to U (E) are highlighted in red.
Fig. 2. Rate and accuracy of mRNA translation in wild-type and mutant mitochondrial hybrid ribosomes. (A) AUG(UUU)12 mRNA-directed incorporation of
phenylalanine and leucine into oligopeptides synthesized by ribosomes containing either a wild-type mitochondrial, mutant A1555G, or mutant C1494U
decoding site (mean SD; n 3). M. smegmatis wild-type ribosomes are included for comparison. For leucine per phenylalanine ratios, see Table 1. (B) Relative
bioluminescence in luciferase synthesis assays (■) and total leucine incorporation () by mitochondrial hybrid and mutant A1555G ribosomes (mean SD; n
3). Bacterial wild-type ribosomes are included for comparison. For luciferase activity per amino acid incorporation ratios, see Table 2.
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The codon ambiguity exploited in the AUG(UUU)12 assay is
located at the third position. Distinction of the third position
is relevant for mixed codon boxes, where the third codon base is
important for discriminating between the correct cognate or
wobble codons, and the near-cognate codons, e.g., UUU/C for
Phe versus UUA/G for Leu, CAU/C for His versus CAA/G for
Gln, AAU/C for Asn versus AAA/G for Lys, GAU/C for Asp
versus GAA/G for Glu (18). To determine ribosome fidelity in
translation of a natural mRNA, we used a luciferase-encoding
mRNA to analyze synthesis of luciferase based on a coupled
transcription–translation assay. The functional enzymatic activ-
ity of firefly luciferase [bioluminescence measured as relative
fluorescence units (RFU)] was determined and related to the
amount of amino acids incorporated (measured as [3H]leucine
incorporation). Compared with wild-type bacterial and mito-
chondrial hybrid ribosomes, the mutant A1555G hybrid ribo-
somes incorporated similar amounts of amino acids in quanti-
tative terms. This observation indicates that the A1555G
mutation does not grossly affect ribosome mechanics nor blocks
a rate-limiting step in polypeptide synthesis. However, in qual-
itative terms, the mutant produced 50% less functional enzy-
matic activity per amino acid incorporated (Fig. 2B and Table 2).
This finding would also be compatible with miscoding, as amino
acid misincorporation during the synthesis of luciferase (550 aa
in length) would be expected to reduce the enzymatic activity
(19), thereby diminishing the level of luminescence without
grossly affecting the overall amount of protein synthesized. To
distinguish misincorporation from premature termination as
cause of decreased luciferase activity, we analyzed the synthe-
sized luciferase by SDS/PAGE and autoradiography. Mutant
and wild-type mitochondrial hybrid ribosomes produced the
same level of full-length protein (SI Fig. 6).
To study the effect of aminoglycosides on translational fidelity
of the deafness alleles, we determined tobramycin-induced mis-
incorporation of leucine in the AUG(UUU)12-mRNA transla-
tion assay. Fig. 3 shows the dose-dependent exacerbation of
translation infidelity in mutant mitochondrial hybrid ribosomes.
Wild-type mitochondrial ribosomes are affected only slightly at
drug concentrations 50 M. The intrinsic infidelity of the
A1555G and C1494Umutants, however, is further aggravated by
drug concentrations of as little as 2 M.
Most nucleotides in 16S rRNA helices 18, 34, and 44 that form
the small subunit decoding site are universally conserved, al-
though subtle but significant variations have evolved in helix 44.
Although the hybrid ribosomes in this study do not carry a
complete mitochondrial A site, transplanting the mitochondrial
version of helix 44 revealed that, in comparison to the wild-type
mitochondrial helix, the disease-associated mutation resulted in
significant misreading. How to explain that the deafness muta-
tions C1494U and A1555G result in mistranslation? Kinetic
models for tRNA selection suggest that the ribosome discrimi-
nates between cognate and noncognate tRNAs by induced fit
(20). At the structural level, decoding is linked to conformational
changes, in which A1492, A1493, and G530 (E. coli numbering)
interact intimately with the minor groove of the first two
codon-anticodon base pairs, thus allowing for discrimination
between cognate and noncognate tRNAs (21) and to initiate
transition of the ribosome from an open to a closed form (22).
The internal, asymmetric loop containing the bulged-out nucle-
otides A1492 and A1493 is closed by nucleotides of the lower
stem of helix 44 (Fig. 1A). Compared with the bacterial A site,
where the loop is closed by a Watson–Crick C1409–G1491
interaction, the internal loop in the mitochondrial A site is able
to adopt an extended conformation becoming closed further
down the helix by a C1495–G1554 base pair (Fig. 1B). Both the
C1494U and the A1555G mutation replace the noncanonical
C1494A1555 interaction by a Watson–Crick base pairing, thus
shortening the extended conformation of the mitochondrial
loop. To investigate a possible effect of internal loop closure on
mitochondrial decoding accuracy, we introduced a C1493–
G1556 base pair to the mitochondrial hybrid (SI Fig. 7B). In
contrast to a C1494–G1555 interaction, introduction of the
C1493–G1556 base pair did not result in miscoding (Table 1 and
SI Fig. 7). This finding indicates that closing the bulge does by
itself not affect the error rate of mRNA decoding.
The base-pairing pattern of the mitochondrial A1555G or
C1494U decoding site resembles that of the bacterial A site
carrying a G1491C mutation. In both sites, the CC opposition at
position 1409–1491 (mitochondrial 1493–1556) is followed by a
Watson–Crick base pair 1410–1490 (mitochondrial 1494–1555,
as depicted in SI Fig. 8A). To test whether this more general
pattern accounts for the translation phenotype observed in
A1555G and C1494U mutant mitochondrial hybrid ribosomes,
we determined the translation fidelity of purified G1491C
bacterial ribosomes. We found that the bacterial G1491C de-
coding site shows no significant misreading, but instead exhibits
a translation fidelity that compares well with that of wild-type
bacterial and wild-type mitochondrial decoding sites (SI Fig.
8B). This observation indicates that translation fidelity also
depends on base-pair interactions within the lower stem of helix
44, which is part of the entire mitochondrial region transplanted,
Table 1. Capacity and accuracy of amino acid incorporation
Decoding site
AUG(UUU)12-directed amino acid incorporation
Phe, pmol Leu, pmol Leu/Phe
M. smegmatis 31 1.3 0.04
Mitochondrial 25 1.2 0.05
A1555G 29 8.5 0.29
C1494U 33 4.4 0.13
C1556G 29 0.7 0.03
Amino acid incorporation is given as the mean amount of [14C]phenylala-
nine and [3H]leucine incorporated by 5 pmol of purified ribosomes after
60-min incubation with AUG(UUU)12 mRNA as template (n  3). See Fig. 2A
and SI Fig. 7 for corresponding time curves and standard deviations.
Table 2. Ribosomal accuracy in luciferase synthesis
Decoding site
Relative luciferase activity per [3H]leucine
incorporation, RFU/dpm
10 min 20 min 30 min
M. smegmatis 0.29 0.22 0.25
Mitochondrial 0.24 0.20 0.29
A1555G 0.11 0.12 0.13
Fig. 3. Aminoglycoside-induced exacerbation of translation infidelity.
Dose–response curves show tobramycin-induced misincorporation of leucine
per phenylalanine by wild-type, A1555G, and C1494U mitochondrial hybrid
ribosomes after 60 min incubation with an AUG(UUU)12 mRNA template
(mean  SD; n  3).
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and which is significantly different from its bacterial counterpart
(Fig. 1 and SI Fig. 8A).
For studying a mechanism for mutation-induced miscoding at
the structural level, we made two assumptions: first, the con-
formation of the decoding region in the native and mutated
mitochondrial ribosomes is identical to that of its bacterial
counterpart, except for the consequences of known sequence
differences; second, the mutations influence their immediate
vicinity. For the human cytosolic A site, two theoretical possi-
bilities for a noncanonical CA base pair have been described
based on RNA oligonucleotides: one with a protonated adenine
shifted to the minor groove side, the other with a nonprotonated
adenine shifted to the major groove side (23). The former is
practically superimposable on the Thermus thermophilus struc-
ture (24, 25) and can explain how codon–anticodon interactions
are monitored to ensure translation fidelity. For the latter, no
biological correlate has been provided. Modeling the mitochon-
drial decoding site on the Thermus structure revealed that the
C1494A1555 interaction is established by a slight rotation of
A1555 toward the outline of helix 44 (Fig. 4). This motion is
accompanied by the rotation of C1494 into the helix to create an
acceptable donor–acceptor relationship between the adenine
and the cytosine. This rotation would increase the surface area
between H44 and H27. By introducing a Watson–Crick base
pairing, as in C1494–A1555G and C1494U–A1555, nucleotide
1555 will be rotated back into H44, thus reducing the contact
between H44 and H27. Destabilizing the interaction between
H44 and H27 could make a relative movement between H27 and
H44 easier. Such a movement is likely to be part of the induced
conformational change required in decoding (22, 26), and
lowering the energetic penalty for the change would allow
near-cognate tRNAs to be accepted more easily. According to
this interpretation, rotation of residue 1555 should be affected
by the relative strength of the 1494–1555 interaction: compared
with a U–A interaction, a C–G pair would limit the possibility of
nucleotide 1555 to escape its displacement imposed by base-
pairing with nucleotide 1494; the presence of three as compared
with two H bonds provides additional binding energy and makes
G–C base pairs intrinsically more stable than A–U pairs. This
prediction is in line with the finding that the A1555G mutation
results in a more pronounced misreading than the C1494U
mutation.
Simple single-cell prokaryotic organisms are apparently able
to tolerate significant misreading (27, 28), as also evidenced by
the viability of the A1555G and C1494U hybrid mutants. How-
ever, the situation in complex multicellular eukaryotes and in
highly specialized tissues is notably different. Misfolded proteins
have been implicated in a variety of diseases (29), in particular
involving cell types that have limited ability to regenerate by cell
division. At least two mechanisms may account for the disease
phenotype conferred by mistranslation: dysfunctional proteins
andmisfolded protein response (30). The 13 proteins encoded by
human mtDNA and translated by mitochondrial ribosomes are
subunits of the respiratory chain and oxidative phosphorylation
pathway at the inner mitochondrial membrane. Lymphoblastoid
cell lines with mutations in mitochondrial 12S rRNA have been
reported to show decreased rates of oxygen consumption (9, 10).
In cell lines of patients with the A1555G mutation no alterations
of mitochondrial translation products at the level of electro-
phoretic mobility were found (31). This observation is compat-
ible with our luciferase data in the mitochondrial hybrid ribo-
somes, which demonstrate that mutation-mediated misreading
manifests primarily at the level of functional activity of the
translated protein by missense rather than by nonsense decoding
(SI Fig. 6). Increased mistranslation of mitochondrial genes
might also account for a misfolded protein response to result in
the cochlear alterations observed in symptomatic and asymp-
tomatic carriers of the A1555G mutation (11).
Identification of misreading as key mechanism in pathogenesis
also allows us to integrate the role of the nuclear background in
disease manifestation and address the association of the A1555G
and C1494U mutations with aminoglycoside-induced deafness.
The nuclear-encoded proteins thus far linked to the expression
of the deafness phenotype are involved in mitochondrial tRNA
or rRNA modifications (32–34). On the basis of a misreading-
prone ribosome, any change in translational efficiency, regard-
Fig. 4. Structural interpretation of mutation A1555G and C1494U. (A) The interface of 16S rRNA helices 44 and 27 in the crystal structure of T. thermophilus
ribosomes (24), showing the bacterial G1410–C1490 base pair, which corresponds to the homologous C1494A1555 interaction in human mitochondrial 12S rRNA.
(B) Enlarged view into the vicinity of C1490. The arrow indicates the rotation that C1490 has to undergo (Upper) to create a noncanonical CA interaction present
in mitochondrial ribosomes (Lower). This rotation increases the interface area between helix 44 and helix 27. Note that owing to the position of nucleotide 1556,
the mutation C1556G (E. coli G1491) should have no effect on the interface area.
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less of its specific mechanism of action, would further impair
mitoribosome function, to aggravate translational dysfunction
beyond the threshold required to result in the phenotypic
expression of severe hearing loss that is associated with muta-
tions A1555G and C1494U. Likewise, the misreading phenotype
of the A1555G and C1494U mutant mitochondrial ribosomes is
significantly exacerbated by aminoglycoside antibiotics.
Although the basis for the tissue specificity of disease expres-
sion is unclear, the biochemical phenotype of the mitochondrial
deafness alleles, as revealed by the study of hybrid ribosomes, is
identical to that of aminoglycoside action, i.e., increased mis-
translation. Together with the dose-related, irreversible ototox-
icity of aminoglycosides, which presumably at least in part
reflects drug-mediated dysfunction of the mitochondrial ribo-
some (8), we conclude that the findings we observe are signif-
icant in understanding the mechanisms of mitochondrial deaf-
ness. We can presently not exclude that, in addition to
mistranslation, other aspects of ribosome function may result in
pathogenic properties of the mutant. Although additional effects
may be involved, our results provide a mechanistic link between
mtDNAdeafness mutations and pathogenesis. The experimental
model developed here may help in the identification of prokary-
otic homologues of nuclear genes modifying phenotypic expres-
sion of the disease and in the design of RNA-specific agonists for
treatment. As a further outcome of our work, we note that
identification of error-prone protein synthesis in mitochondria
with an A1555G mutation also allows testing of the long-
standing hypothesis of mitochondrial dysfunction and aging (35).
Materials and Methods
Construction of Mutant Strains with Hybrid Ribosomes. The recently described
strain M. smegmatis rrnB (16) was used for all genetic manipulations. Site-
directed mutagenesis of its single rRNA operon was performed by PCR mu-
tagenesis with hybrid rDNA oligonucleotides comprising the wild-type or
mutant mitochondrial helix 44 decoding site sequence. The resulting hybrid
gene fragment was cloned into an integration-proficient plasmid used to
transformM. smegmatisrrnB. Transformants were selected on LB agar plates
containing 20 g/ml paromomycin for gene replacement by homologous
recombination. After several attempts to introduce various parts of the mi-
tochondrial H44 into bacterial ribosomes by site-directed mutagenesis, we
were finally able to generate recombinant M. smegmatis cells where the
central 34-nt part of the bacterial H44 had been replaced by its mitochondrial
counterpart. Successful replacement of the bacterial decoding site sequence
with the mitochondrial sequence was controlled by sequence analysis of the
chromosomal rrnA locus. Transplanting the mitochondrial decoding sites into
the bacterial ribosome affected the generation times of the resulting M.
smegmatismutants slightly (mitochondrial hybrid 5.1 h; C1494U 4.9 h; A1555G
6.0 h; as compared with M. smegmatis rrnB 3.7 h).
Isolation and Purification of Ribosomes. Ribosomes were isolated from bacte-
rial cell pellets as described (36). For further fractionation, isolated ribosomes
were resuspended in overlay buffer [20 mM TrisHCl (pH 7.4), 60 mM NH4Cl,
5.25 mM MgCl2, 0.25 mM EDTA, 3 mM 2-mercaptoethanol, and 5% sucrose]
loaded on a sucrose gradient (10–40% sucrose in overlay buffer) and centri-
fuged in a Beckman Ti 15 rotor at 28,000 rpm for 18 h. Gradient fractions were
collected by unloading the zonal rotor with 50% sucrose in overlay buffer. The
70S ribosome-enriched fractions were pooled according to the absorption
profile at 260 nm, and applied to centrifugation at 180,000  g for 20 h. The
final ribosome pellets were resuspended in buffer A [50 mM TrisHCl (pH 7.5),
70 mM NH4Cl, 30 mM KCl, and 7 mM MgCl2], incubated for 30 min at 4°C,
dispensed into aliquots, and stored at 80°C after shock freezing in liquid
nitrogen. 70S ribosome concentrations were determined by absorption mea-
surements on the basis of 23 pmol per A260 unit. Integrity and functional
activity of purified 70S ribosomes was determined by analytical ultracentrif-
ugation and by assessing their capacity to form initiation complexes, as
described (36).
Cell-Free AUG(UUU)12 Translation Assays. Cell-free translation reactions in buffer
A (pH 7.5) were prepared on ice and contained M. smegmatis tRNAbulk (0.5
mg/ml), amino acids mixture (30M each) lacking phenylalanine and/or leucine,
10% (vol/vol) S100 extract, energy mix (1 mM DTT, 1 mM GTP, 4 mM ATP, and 5
mM phosphoenolpyruvate), pyruvate kinase (0.1 mg/ml), and polyamines (2 mM
spermidine and 8 mM putrescine). The reaction mixture was preincubated with
30 M [14C]phenylalanine (110 mCi/mmol) and/or 30 M [3H]leucine (500 mCi/
mmol) at 37°C for 15 min. The translation reaction was started by addition of
ribosomes to a final concentration of 0.25 M and AUG(UUU)12-mRNA
[5-GCGGCAAGGAGGUAAAUAAUG(UUU)12UAAGCAGG-3, obtained from
Dharmacon] to 1 M; in experiments studying tobramycin-induced misreading,
the drug was added simultaneously. After incubation at 37°C for the times
indicated, the reaction was stopped by addition of KOH to 0.5 M and subsequent
hydrolysis at 37°C for 30 min. Synthesized polypeptides were precipitated with
200 l of 5% trichloroacetic acid (TCA) for 10 min on ice and bound to filters.
Filter-bound polypeptides were washed with cold 30% 2-propanol, dissolved in
10 ml of scintillation mixture, and quantified.
Cell-Free Luciferase Translation Assays. Purified 70S hybrid ribosomes were
used in a coupled transcription-translation reaction of firefly luciferase (plas-
mid pBESTluc; Promega). A typical reaction (30 l volume) contained 0.25 M
70S ribosomes, 600 ng DNA, 40% (vol/vol) of M. smegmatis S100 extract, 100
M amino acid mixture minus leucine, 1.7 M [3H]leucine (59 Ci/mmol), and
RNasin (40 units; Promega). rNTPs, tRNAs, and energy were supplied by the
addition of commercial S30 Premix Without Amino Acids (Promega). The
reaction mixture was incubated at 37°C and stopped on ice. Fifteen microliters
of the reaction volume was added to 100 l of luciferase assay substrate
(Promega), and the bioluminescence was measured in a luminometer (Bio-Tek
Instruments; FL 800). In the remaining 15 l of reaction volume, polypep-
tides were hydrolyzed, precipitated, applied to a GF/A filter (Whatman), and
washed three times with 3 ml of ice-cold 5% TCA. Filters were air-dried for 10
min, and [3H]leucine incorporation was quantified in 10 ml of scintillation
mixture.
Structural Modeling. Modeling the mitochondrial decoding site on the Ther-
mus thermophilus structure (24) was done manually, according to the follow-
ing procedure: (i) substituting the bacterial residues G1410 with C and C1490
with A according to the homologous positions in mitochondrial ribosomes
(C1494A1555), using the backbone conformation as a guide; (ii) fitting A1555
into the helix so that a noncanonical CA base pair could be formed; and (iii)
combining attempts to obtain a relevant H bond with estimating (by actual
measurements) the deviation of the new structure from a perfect helix and
searching for structural elements that can be exploited for the extra stabili-
zation needed for the slightly shifted-rotated region of the helix. In addition
to the slight rotation, a small shift was included in the modeling; the latter,
however, is of negligible magnitude at the resolution level of the structure.
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SUPPORTING INFORMATION 
 
 
 
SI Figure 5: Secondary structure of the rRNA decoding site in yeast mitochondria. 
(A) The ribosomal decoding site of Saccharomyces cerevisiae mitochondrial 
ribosomes; rRNA residues are numbered according to the position in yeast mtDNA. 
(B) Mitochondrial mutant decoding site carrying a cytosine to guanine mutation at 
position 1477 (corresponding to E. coli position 1409). Note that yeast mt rRNA 
position 1477 is not homologous to human mt rRNA position 1494 but to position 
1493 (compare to Figure 1 in the article). In addition, the lower stem of the yeast 
mitochondrial rRNA helix resembles its bacterial homologue helix 44 rather than its 
human mitochondrial counterpart: e.g. a Watson-Crick interaction at yeast mt rRNA 
positions C1477–G1583 (bacterial C1409–G1491) and G1478–C1582 (bacterial 
G1410–C1490), the corresponding human mt rRNA positions C1493●C1556 and 
C1494●A1555 are no Watson-Crick interactions. 
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SI Figure 6: Capacity and accuracy of translation in mitochondrial hybrid and 
C1556G ribosomes. AUG(UUU)12 mRNA-directed incorporation of [14C]-
phenylalanine (□) and [3H]-leucine (■) in a cell-free translation assay (mean ± s. d.; 
n = 3). (A) Bacterial hybrid ribosomes with a wild-type mitochondrial decoding site. 
(B) Mutant mitochondrial hybrid ribosomes with a cytosine to guanine alteration at 
position 1491 (mtDNA 1556), which creates a canonical C–G base pair interaction. 
The ratio of leucine per phenylalanine incorporation is given in Table 1. 
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SI Figure 7: To distinguish misincorporation from premature termination we analyzed 
[35S]-methionine-labeled proteins synthesized in cell-free translation assays by 
purified bacterial and mitochondrial hybrid ribosomes using SDS-PAGE (12%) 
fluorography. Mutant A1555G and wild-type mitochondrial hybrid ribosomes 
produced the same level of full-length proteins, as assessed by translation of 
luciferase mRNA in a coupled transcription-translation reaction and by translation of 
L1 mRNA in T7-mRNA driven translation. (A) Proteins translated during luciferase 
coupled transcription-translation showing full length luciferase (61 kDa), truncated 
luciferase transcribed from an internal start codon (48 KDa), and β-lactamase 
(31.5 kDa). (B) T7-mRNA-driven synthesis of Methanococcus jannaschii ribosomal 
protein L1 (25 kDa). 
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SI Figure 8: Comparison of the mitochondrial A1555G mutant with the bacterial 
G1491C mutant. (A) Structural comparison of the base-pairing pattern in the 
ribosomal A site. Both the A1555G and the G1491C mutant are characterized by a 
C•C opposition at position 1409-1491 (mitochondrial 1493-1556, respectively) and an 
adjacent C-G Watson-Crick pair. (B) Translation phenotypes of wild-type and mutant 
bacterial and mitochondrial decoding sites. The amount of [14C]-phenylalanine and 
[3H]-leucine incorporated in a AUG(UUU)12 mRNA-driven translation assay is 
presented. 
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Aminoglycoside ototoxicity has been related to a surprisingly large
number of cellular structures and metabolic pathways. The finding
that patients with mutations in mitochondrial rRNA are hypersus-
ceptible to aminoglycoside-induced hearing loss has indicated a
possible role for mitochondrial protein synthesis. To study the
molecular interaction of aminoglycosides with eukaryotic ribo-
somes, we made use of the observation that the drug binding site
is a distinct domain defined by the small subunit rRNA, and
investigated drug susceptibility of bacterial hybrid ribosomes car-
rying various alleles of the eukaryotic decoding site. Compared to
hybrid ribosomes with the A site of human cytosolic ribosomes,
susceptibility of mitochondrial hybrid ribosomes to various ami-
noglycosides correlated with the relative cochleotoxicity of these
drugs. Sequence alterations that correspond to the mitochondrial
deafness mutations A1555G and C1494T increased drug-binding
and rendered the ribosomal decoding site hypersusceptible to
aminoglycoside-induced mistranslation and inhibition of protein
synthesis. Our results provide experimental support for aminogly-
coside-induced dysfunction of the mitochondrial ribosome. We
propose a pathogenic mechanism in which interference of amino-
glycosides with mitochondrial protein synthesis exacerbates the
drugs’ cochlear toxicity, playing a key role in sporadic dose-
dependent and genetically inherited, aminoglycoside-induced
deafness.
decoding  mitochondria  ribosomes  toxicity  translation
Low cost and high efficacy make aminoglycosides a commonchoice for treatment of serious infections caused by gram-
negative bacilli, including endocarditis, sepsis, pneumonia, py-
elonephritis, and multidrug-resistant tuberculosis (1). Unfortu-
nately, aminoglycosides are both nephrotoxic and ototoxic.
Although renal impairment is in general mild and reversible,
ototoxicity results from drug-induced apoptosis of cochlear and
vestibular hair cells and is irreversible (2, 3). Ototoxicity of
aminoglycoside antibiotics occurs both in a dose-dependent and
in an inherited idiosyncratic fashion. Despite attempts to limit
drug doses and to monitor blood levels carefully, measurable
signs of hearing loss are found in 20% of patients receiving
aminoglycosides (2). Familial cases of aminoglycoside-induced
deafness are maternally transmitted and linked to mutations in
mitochondrial DNA (mtDNA) (4–6).
The mechanisms by which aminoglycoside antibiotics exert
their toxic effects are controversial. A surprisingly large and
diverse number of effects have been associated with aminogly-
cosides. Aminoglycosides have been reported to affect DNA,
RNA, and protein synthesis; energy metabolism and ion trans-
port; and synthesis or degradation of prostaglandins, ganglio-
sides, mucopolysaccharides and lipids (2). In addition, it has
been hypothesized that aminoglycosides may form cochleotoxic
metabolites. Antioxidants apparently attenuate aminoglycoside-
induced hearing loss, pointing to a role of the mitochondrion, an
organelle involved in oxidation, as a target of ototoxic drugs (7,
8). Genetic analyses of individuals hypersensitive to aminogly-
cosides have identified mutations in mitochondrial rRNA. Tran-
sition mutations in the mitochondrial small ribosomal RNA
gene, namely A1555G and, less frequently C1494T, have been
identified as primary genetic traits in aminoglycoside-induced
deafness (4, 6, 9). A1555G and C1494T both map to the
aminoacyl-tRNA acceptor site (A site) of the small ribosomal
subunit. The bacterial A-site rRNA is target for aminoglycoside
antibiotics, which exert their antibacterial effect at the level of
the prokaryotic ribosome (10–13). Aminoglycosides affect pro-
tein synthesis by inducing codon misreading and by inhibiting
translocation of the tRNA-mRNA complex (14, 15). The basis
for aminoglycoside selectivity is presumably their preferential
binding to the bacterial as opposed to eukaryotic ribosomes (13,
16, 17).
The high copy number of mtDNA inmitochondria and the vast
number of mitochondria in a single cell have frustrated any
attempt of genetic manipulation of mitochondrial rRNA in lower
and higher eukaryotes. Model oligonucleotides designed to
mimic the drug-binding site have been used to investigate various
aspects of aminoglycoside-ribosome interaction (18–22). How-
ever, conclusions derived from the study of model A-site oligo-
nucleotides are compromised by several findings: (i) in contrast
to drug susceptibility of complete ribosomes, binding affinities of
aminoglycosides to prokaryotic decoding region constructs are
not very sensitive to mutations within the RNA-binding region
(23); (ii) in vivo drug susceptibilities of mutant ribosomes and in
vitro binding affinities using variants of model A-site oligonu-
cleotides may or may not correlate (24–26); (iii) the exquisite
specificity of aminoglycosides for the prokaryotic as opposed to
the eukaryotic cytosolic ribosome contrasts with the observation
that these drugs bind to eukaryotic decoding-site constructs with
approximately the same affinity as found for their prokaryotic
counterpart (23, 24); and (iv) while there is evidence that
mitochondrial ribosomes are susceptible to aminoglycosides (13,
27), oligonucleotides mimicking the mitochondrial A site do not
bind aminoglycosides to any significant extent (24, 28).
Using gene-shuffling experiments, we have previously re-
placed the A-site residues of helix 44 (H44) in bacterial 16S
rRNA with various eukaryotic homologues, demonstrating that
the A-site rRNA behaves as an autonomous domain, which can
be exchanged between different species for study of function (29,
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30). Replacement of a 34-nucleotide portion of bacterial 16S-
rRNA helix 44 with its human homologues resulted in rRNA-
decoding sites virtually identical to that in cytosolic and mito-
chondrial ribosomes. Here we used hybrid bacterial ribosomes
carrying distinct alleles of the mitochondrial decoding site to
study aminoglycoside susceptibility of wild-type and mutant
mitochondrial rRNA.
Results and Discussion
The in vivo activity of various 2-deoxystreptamine antibiotics
against isogenic Mycobacterium smegmatis strains carrying mi-
tochondrial-bacterial hybrid ribosomes was tested in minimal
inhibitory concentration (MIC) assays, which determine growth
inhibition at the whole-cell level. Compared to bacterial ribo-
somes, which were found to be unanimously susceptible to all
aminoglycosides tested, the hybrid ribosomes with a wild-type
mitochondrial H44 revealed a heterogeneous drug susceptibility
pattern, with MIC values ranging from 32 to 1,024 g/ml (Table
1). The ratio of MIC mitochondrial hybrid to MIC wild-type M.
smegmatis varied from 64-fold (gentamicin, amikacin) to 256-
fold (netilmicin, kanamycin), providing a relative measure of the
drug-target selectivity of different 2-deoxystreptamine antibiot-
ics. We next investigated recombinants where the bacterial H44
has been replaced by mitochondrial deafness alleles correspond-
ing to mtDNA mutations A1555G and C1494T. The resulting
mutant mitochondrial hybrid ribosomes differ from the wild-
type mitochondrial hybrid only in 16S rRNA residues 1490 and
1410; compare Fig. 1C to Fig. 1 D and E (bacterial 16S rRNA
residues are numbered according to Escherichia coli nomencla-
ture). The presence of the A1555G or the C1494T mutation
increased drug susceptibility of cells carrying the mitochondrial
hybrid ribosomes by 4- to 16-fold (see Table 1).
For a more detailed study of the mt A1555G and C1494T
alleles, we studied purified hybrid ribosomes in cell-free trans-
lation reactions. We first used an AUG(UUU)12-mRNA tem-
plate, as this message allows determination of drug-induced
inhibition of polypeptide synthesis and amino acid misincorpo-
ration. Dose-response curves of aminoglycoside-induced inhibi-
tion of phenylalanine incorporation were analyzed to define the
IC50 values of the individual 2-deoxystreptamines. Both the
A1555G and the C1494T genotypes were more susceptible to
aminoglycoside antibiotics than the wild-type mitochondrial
decoding site, as indicated by the finding that significantly less
drug concentrations were required to inhibit AUG(UUU)12
mRNA-driven polyPhe synthesis [see Fig. 2A, Table 2, and
supporting information (SI) Fig. S1].
Aminoglycosides are known to affect the translational fidelity
of ribosomes by inducing misreading of the genetic code (14).
For study of aminoglycoside-induced mistranslation we used the
AUG(UUU)12-driven polypeptide synthesis assay to determine
Table 1. Minimal inhibitory concentrations (g/ml) of aminoglycoside antibiotics
Aminoglycoside
A-site rRNA
Bacteriala
Mitochondrial (mt)
hybrid
mt A1555G
hybrid
mt C1494T
hybrid
Neomycin B 0.5 16–32 8 8
Paromomycin 1  1,024 256–512 256–512
Kanamycin A 1 256–512 16–32 16
Tobramycin 1 128 16 16
Amikacin 0.5 32–64 2–4 2–4
Gentamicin 1 64–128 16–32 16–32
Netilmicin 2 512–1024 64 64–128
aM. smegmatis wild-type rRNA
Fig. 1. Secondary structure of rRNA helix 44 in the ribosomal decoding site. (A) Decoding site of M. smegmatis wild-type ribosomes; rRNA nucleotides are
numbered according to the bacterial nomenclature (i.e., homologous E. coli 16S rRNA positions). (B) Decoding site of human mitochondrial ribosomes; rRNA
residues are numbered according to the mitochondrial nomenclature. (C–E) Mitochondrial decoding sites within human-bacterial hybrid ribosomes: wild type
sequence (C) and deafness-associated alterations adenine to guanine at position 1490 (corresponding to mitochondrial mutation A1555G) (D); cytosine to uracil
mutation at position 1410 (corresponding to mitochondrial mutation C1494T) (E). Nucleotide positions depicted in blue represent residues that are specific for
human rRNA; nucleotide positions in red highlight the pathogenic mutations; the transplanted helix is boxed. (F) Decoding site of the M. smegmatis G1491C
mutant.
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the relative amount of near-cognate leucine incorporation com-
pared to incorporation of the cognate amino acid phenylalanine
in the presence of various concentrations of gentamicin. Relative
incorporation of [3H]-labeled leucine versus [14C]-labeled phe-
nylalanine was determined and plotted against gentamicin con-
centration. Introduction of the A1555G and C1494T alteration
rendered the mitochondrial hybrid ribosomes highly susceptible
to aminoglycoside-induced misreading (Fig. 2B; see also Fig.
S2). In quantitative terms, the amount of gentamicin-induced
misreading (calculated as leucine per phenylalanine incorpora-
tion) in A1555G and C1494T mutant hybrid ribosomes was up
to 1.75 leucine per phenylalanine, as compared to a maximum of
0.2 leucine per phenylalanine for hybrid ribosomes with a
wild-type mitochondrial decoding site.
To study the effect of aminoglycoside antibiotics on translation
of a more natural mRNA template, we tested wild-type andmutant
mitochondrial hybrid ribosomes in a cell-free luciferase synthesis
assay. As depicted in Fig. 2C, Table 3, and Fig. S3, the allele- and
drug-specific inhibition of luciferase synthesis essentially correlated
with the results of the MIC and AUG(UUU)12 assays. Drug-
mediated inhibition of luciferase synthesis was significantly in-
creased in A1555G and C1494T mutant ribosomes.
The basis for the selectivity of aminoglycosides is presumably
their preferential binding to bacterial as opposed to eukaryotic
ribosomes (10, 13, 16, 17). In particular, 16S rRNA nucleotides
1408, 1409, and 1491 of helix 44 have been shown to be critical
for drug-binding by forming direct contacts with ring I of the
2-deoxystreptamines (12, 13, 16, 17, 26, 31–38) (see Fig. S4 for
the chemical structures of aminoglycosides used in this study). In
the absence of X-ray structures for aminoglycosides complexed
to the mitochondrial ribosome, we can rationalize our findings
on data invoked from the study of bacterial ribosome-drug
complexes (12, 39). The rRNA secondary structure of the drug
binding site in mitochondrial A1555G and C1494T mutant
ribosomes resembles that of bacterial ribosomes with a G1491C
alteration in that the C1409-C1491 opposition is accompanied by
a 1410–1490 Watson–Crick pair (see Fig. 1). The bacterial
G1491C ribosome shows a drug-susceptibility phenotype that is
virtually superimposable on that found for the mitochondrial
deafness alleles (see Table S1 for comparison). To determine
whether the affinity of aminoglycosides to mutant mitochondrial
decoding sites corresponds to that of the bacterial G1491C
decoding site, we probed gentamicin binding by chemical foot-
printing experiments. Bacterial wild-type ribosomes showed
drug-mediated protection from dimethyl sulfate (DMS) modi-
fication at G1405 (N-7), which is in good agreement with
previous reports on aminoglycoside protection in bacterial 16S
rRNA (34). Wild-type mitochondrial hybrid ribosomes showed
little protection, while mutant mitochondrial A1555G and
C1494T hybrid ribosomes showed a concentration-dependent
protection of G1405 that resembles the dose-response curve
observed with bacterial G1491C ribosomes (Fig. 3). Thus, bind-
ing of aminoglycosides to ribosomes with an adenine at 16S
rRNA position 1408, appears to be mainly determined by the
structural geometry of base pairs 1409–1491 and 1410–1490.
When studying drug-induced miscoding, we found that the
decoding accuracy of bacterial G1491C ribosomes is barely
affected by aminoglycoside antibiotics. In absolute terms and in
contrast to the mitochondrial A1555G and C1494T deafness
mutants, the bacterial G1491C ribosomes showed little drug-
Fig. 2. Aminoglycoside susceptibility of mutant and wild-type mitochondrial hybrid ribosomes. Dose-response curves of wild-type mitochondrial (red squares),
mutant A1555G (green triangles), and mutant C1494T (blue inverted triangles) hybrid ribosomes; bacterial ribosomes (black circles) are included for comparison.
(A) Gentamicin-induced inhibition of [14C]-phenylalanine incorporation (n  3;  SD.). The 100% value corresponds to 25 to 30 pmol Phe incorporation.
Corresponding IC50 values of gentamicin and selected aminoglycoside antibiotics are presented in Table 2. (B) Gentamicin-induced increase in misincorporation
of the near-cognate [3H]-leucine relative to the drug-free control (n 3; SD.). (C) Gentamicin-induced inhibition of luciferase synthesis relative to the drug-free
control (n  3;  SD.). Corresponding IC50 values for gentamicin and selected aminoglycoside antibiotics are presented in Table 3.
Table 2. Aminoglycoside-induced inhibition of AUG(UUU)12-driven phenylalanine
incorporation (IC50, M)
Aminoglycoside
A-site rRNA
Bacteriala
Mitochondrial (mt)
hybrid
mt A1555G
hybrid
mt C1494T
hybrid
Neomycin B 0.2  0.0 209  61 3.1  0.3 3.7  0.7
Paromomycin 0.7  0.1  500 124  35 116  20
Kanamycin A 1.2  0.2  500 20  2 95  29
Tobramycin 0.7  0.1  500 15  3 70  23
Amikacin 0.8  0.1  500 7.1  0.8 13  3
Gentamicin 1.3  0.2  500 13  2 62  16
Netilmicin 1.2  0.3  500 71  10 331  84
IC50 values represent the drug concentrations in M that are required to inhibit AUG(UUU)12-driven phenyl-
alanine incorporation to half-maximal extent. A representative graph showing phenylalanine incorporation
plotted against gentamicin concentration is shown in Fig. 2A.
aM. smegmatis wild-type rRNA
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induced misreading (see Fig. S2). The bacterial G1491C mutant
and the hybrid deafness ribosomes differ primarily in 16S rRNA
residues 1413 to 1415 and 1485 to 1487, which form the lower
stem of helix 44 (see Fig. 1). At the structural level, helix 44
interacts with helix 27. By modeling, nucleotide alterations in the
lower stem of H44 have been suggested to affect this interaction
and the relative movement between these two helices as part of
the conformational change required in decoding (30). Appar-
ently, the nature of the lower stem plays an important role in
both spontaneous and drug-aggravated miscoding and deter-
mines the translational accuracy of the mutant decoding sites.
Thus, susceptibility of A1555G and C1494T deafness mitoribo-
somes is the result of two mechanisms, which act in concert:
increased drug binding to its target and excessive aggravation of
the mutants’ inherent deficiency in ribosomal accuracy.
Several lines of evidence link aminoglycoside ototoxicity to the
mitochondrial ribosome: (i) mitochondrial ribosomes are struc-
turally more similar to their prokaryotic ancestor than to the
eukaryotic cytosolic homologues; (ii) compared to cytosolic
ribosomes, the mitochondrial ribosomes of higher eukaryotes
exhibit a remarkable degree of aminoglycoside susceptibility
(27) [see Table S2, which compares the drug susceptibility of
hybrid bacterial ribosomes with the A site (H44) of human
cytosolic ribosomes to that of hybrid ribosomes with the mitochon-
drial decoding site]; and (iii) idiosyncratic drug susceptibility is
associated with genetic predisposition, in particular mutations in
mtDNA: 20 to 40% of patients with aminoglycoside-induced
ototoxicity either carry the A1555G or the C1494T mutation in
the 12S rRNA gene (6, 40).
To further assess whether aminoglycoside-induced ototoxicity
is a result of the drugs’ anti-mitoribosomal activity, we compared
the potencies of a series of aminoglycosides to inhibit mitoribo-
some function with their relative cochleotoxicity in humans (41).
The correlation between these two measures (Fig. 4) is consis-
tent with the hypothesis that aminoglycoside-induced cochleo-
toxicity relates to the drugs’ activity against mitochondrial
ribosomes. Further evidence for this hypothesis is provided by
our finding that netilmicin, which displays the least cochlear
toxicity of the clinical aminoglycosides (reviewed in ref. 42), is
significantly less active against hybrid mitochondrial ribosomes
than gentamicin, tobramycin, or amikacin.
In summary, we provide experimental evidence for a mech-
anistic linkage between the mitochondrial A1555G and C1494T
mutations and hypersusceptibility to aminoglycosides, although
the exquisite tissue-specific action of aminoglycoside toxicity
(that is, ototoxicity) is likely to involve additional factors (e.g.,
reactive oxygen species, drug uptake, or polyamine-like activa-
tion of NMDA receptors) (2, 43). Our results provide experi-
mental support for aminoglycoside-induced dysfunction of the
mitochondrial ribosome. We propose a pathogenic mechanism,
in which interference of aminoglycosides with mitochondrial
protein synthesis exacerbates the drugs’ cochlear toxicity, play-
ing a key role in sporadic dose-dependent and genetically
inherited, aminoglycoside-induced deafness. Based upon our
experiments, we suggest a scenario of aminoglycoside hearing
Table 3. Aminoglycoside-induced inhibition of luciferase synthesis (IC50, M)
Aminoglycoside
A-site rRNA
Bacteriala
Mitochondrial (mt)
hybrid
mt A1555G
hybrid
mt C1494T
hybrid
Neamine 1.4 131 32 35
Neomycin B 0.04 0.7 0.5 0.4
Paromomycin 0.03 33 2.4 3.1
Kanamycin A 0.05 15.7 1.2 1.1
Tobramycin 0.02 7.8 0.8 0.9
Amikacin 0.02 7.0 0.4 0.6
Gentamicin 0.03 5.7 0.6 0.7
Netilmicin 0.05 17.6 0.8 2.6
IC50 values represent the drug concentrations in M that are required to inhibit synthesis of functional firefly
luciferase to 50%. Relative luciferase activity plotted against aminoglycoside concentration is shown in Fig. 2C.
aM. smegmatis wild-type rRNA
Fig. 3. Chemical footprints of gentamicin binding to wild-type and mutant
mitochondrial decoding sites in comparison to bacterial wild-type and G1491C
ribosomes. (A) Gentamicin-dependent protection of G1405 in wild-type mi-
tochondrial (red squares), mutant mt A1555G (green triangles), mutant mt
C1494T (blue inverted triangles), and bacterial G1491C (purple diamonds)
decoding sites; wild-type bacterial ribosomes (black circles) are included for
comparison. (B) Corresponding footprinting blots showing primer extensions
starting with U1420. i, bacterial wild type; ii, mt wild type; iii, mt A1555G; iv,
mt C1494T; v, bacterial G1491C.
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loss, which is initiated by mitoribosomal misreading, subse-
quently via activation of downstream signaling pathways, such as
MAPK and JNK (44, 45), misreading results in hair cell death
through apoptosis.
Materials and Methods
Construction of Mutant Strains with Hybrid Ribosomes. The recently described
M. smegmatis mc2 155 SmS rrnB (38) was used for all genetic manipulations.
Site-directed mutagenesis of its single rRNA operon was done by PCR mu-
tagenesis using hybrid rDNA oligonucleotides comprising the wild-type or
mutant mitochondrial helix 44 decoding-site sequence. The resulting hybrid
gene fragment was cloned into an integration-proficient plasmid used to
transformM. smegmatisrrnB. Transformants were selected on LB agar plates
containing 20 g/ml paromomycin for gene replacement by homologous
recombination. Resulting recombinant M. smegmatis cells had the central
34-nucleotide part of the bacterial H44 replaced by its mitochondrial coun-
terpart. Successful replacement of the bacterial decoding-site sequence with
the mitochondrial sequence was controlled by sequence analysis of the chro-
mosomal rrnA locus.
Minimal Inhibitory Concentration Assays. Minimal inhibitory concentrations of
neomycin B, paromomycin, kanamycin A, tobramycin, amikacin, gentamicin,
netilmicin (all Sigma), and neamine were determined by broth microdilution
assays as described previously (46). Neamine was a kind gift of Andrea Vasella,
ETH Zurich. The gentamicin used in this study is a mixture of gentamicin C1,
gentamicin C1a, and gentamicin C2 in a 45:35:30 ratio.
Isolation and Purification of Ribosomes. Ribosomes were purified from bacte-
rial cell pellets as described previously (30). In brief, ribosome particles were
isolated by successive centrifugations and fractionated by sucrose gradient
(10–40%) centrifugation. The 70S ribosome-enriched fraction was pelleted,
resuspended in association buffer, incubated for 30 min at 4 °C, dispensed into
aliquots, and stored at 80 °C following shock freezing in liquid nitrogen.
Ribosome concentrations of 70S were determined by absorption measure-
ments on the basis of 23 pmol ribosomes perA260 unit. Integrity and functional
activity of purified 70S ribosomes was determined by analytical ultra-
centrifugation and by assessing their capacity to form initiation complexes, as
described previously (29).
Cell-free AUG(UUU)12 Translation Assays. Cell-free translation reactions were
done as described previously (30). A reaction mixture containing M. smegma-
tis tRNAbulk, amino acids, S100 extract, energy mix, pyruvate kinase, and
polyamines was preincubated with 30 M [14C]-phenylalanine (110 mCi/
mmol) and/or 30 M [3H]-leucine (500 mCi/mmol) at 37 °C for 15 min. The
translation reaction was started by addition of ribosomes to a final concen-
tration of 0.25 M, AUG(UUU)12-mRNA (5-GCGGCAAGGAGGUAAAUA AUG
(UUU)12 UAA GCAGG-3, obtained from Dharmacon) to 1 M, and aminogly-
coside antibiotics in serial dilutions. Following incubation for 60 min at 37 °C,
the reaction was stopped by addition of KOH, precipitated polypeptides were
collected on filters, and [14C]-phenylalanine or [3H]-leucine were quantified.
Background values for Phe and Leu incorporation were 0.4 to 0.5 pmol at time
zero; the background was not subtracted from the experimental values
determined.
Cell-Free Luciferase Translation Assays. Purified 70S hybrid ribosomes were
used in a coupled transcription-translation reaction as described previously
(29). The reaction mixture was incubated for 60 min at 37 °C, stopped on ice,
and luciferase assay substrate (Promega) was added. Functional protein was
quantified by measuring bioluminescence in a luminometer (Bio-Tek instru-
ments, FLx800).
Footprinting Analyses. DMS modification of 70S ribosomes (20 pmol) was per-
formedin100lbuffercontaining80mMpotassiumcacodylate (pH6.5),100mM
ammonium chloride, 20 mM magnesium chloride, 1 mM DTT, and 0.5 mM EDTA.
Following ribosome activation for 15 min at 37 °C, gentamicin was added and the
reaction mixture was incubated for another 15 min before addition of DMS (6l,
1:10 inethanol).Followinga30-minincubationat37 °C, thereactionwasstopped
by addition of 100 l DMS Stop solution (50 mM Tris, pH 7.5, 300 mM sodium
chloride, 1% SDS, 200 mM -mercaptoethanol). Ribosomes were precipitated
with ethanol, pelleted, resuspended in 200 l 50 mM Tris pH 8, 0.5% SDS, and
extracted with phenol/chloroform. DMS-modified RNA was precipitated with
ethanol and sodium borohydride reduction and aniline-induced strand scission
was performed as described previously (47). Primer extension of 16S rRNA was
performed as described (48), using DNA oligonucleotides complementary to
16S-rRNA nucleotides 1445 to 1421. Air-dried gels were scanned and quantified
using the STORM PhosphorImaging System with ImageQuant 5.2 Software (Am-
ersham Bioscience).
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Fig. S1. Aminoglycoside susceptibility of bacterial hybrid ribosomes in AUG(UUU)12-directed polypeptide synthesis. Dose-response curves of bacterial (black
circles), mitochondrial (red squares), mutant A1555G (green triangles), andmutant C1494T (blue inverted triangles) hybrid ribosomes. Corresponding IC50 values
are given in Table 2.
Hobbie et al. www.pnas.org/cgi/content/short/0811258106 1 of 6
35
Fig. S2. Aminoglycoside-inducedmiscoding relative to a drug-free control in aM. smegmatisG1491Cmutant in comparison tomutantmitochondrial decoding
sites. Dose-response curves ofM. smegmatisG1491C (purple diamonds),mitochondrial (red squares),mutantA1555G (green triangles), andmutant C1494T (blue
inverted triangles) hybrid ribosomes. Bacterial wild-type ribosomes (black circles) are included for comparison.
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Fig. S3. Aminoglycoside-induced inhibition of luciferase synthesis. Dose-response curves of bacterial (black circles), mitochondrial (red squares), mutant
A1555G (green triangles), and mutant C1494T (blue inverted triangles) hybrid ribosomes. Corresponding IC50 values are given in Table 3.
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Fig. S4. Chemical structures of 2-deoxystreptamine antibiotics used in this study.
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Table S1. Minimal inhibitory concentrations (g/ml) against M. smegmatis G1491C mutant in comparison to mutant mitochondrial
hybrids
A-site rRNA
M. smegmatis Mitochondrial (mt) hybrid mt A1555G hybrid mt C1494T hybrid M. smegmatis G1491C
Neomycin B 0.5 16–32 8 8 16
Paromomycin 1  1,024 256–512 256–512 512
Kanamycin A 1 256–512 16–32 16 16–32
Tobramycin 1 128 16 16 16
Amikacin 0.5 32–64 2–4 2–4 4
Gentamicin 1 64–128 16–32 16–32 16–32
Netilmicin 2 512–1,024 64 64–128 128
Hobbie et al. www.pnas.org/cgi/content/short/0811258106 5 of 6
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Table S2. Aminoglycoside susceptibility of the mitochondrial
versus the cytosolic decoding site
MIC (g/ml)
Mitochondrial hybrid Cytosolic hybrid
Neomycin B 16–32  1,024
Kanamycin A 256–512  1,024
Tobramycin 128 1,024
Amikacin 32–64 512–1,024
Gentamicin 64–128  1,024
Netilmicin 512–1,024  1,024
Hobbie et al. www.pnas.org/cgi/content/short/0811258106 6 of 6
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Antibiotics targeting the bacterial ribosome typically bind to highly conserved rRNA 
regions with only minor phylogenetic sequence variations. By mutagenesis of rRNA 
sequences in M. smegmatis ribosomes we reconstructed the effect of characteristic 
rRNA residues on drug activity and provide a rationale for differences in species-
specific drug susceptibility patterns. 
 
The bacterial ribosome is target for many antibacterial agents that interfere with protein 
synthesis, such as aminoglycosides, macrolides, ketolides, oxazolidinones, and lincosamides 
(1, 29). These compounds target different steps involved in translation including decoding, 
peptide bond formation and translocation (24, 31, 34). While different classes of antibiotics 
bind to different ribosomal regions and interfere with different steps of translation, they all 
interact directly with rRNA nucleotides at or near functionally important sites (32, 33). These 
rRNA residues typically show high phylogenetic sequence conservation within bacteria. It is 
unclear whether the minor phylogenetic sequence variations present in the bacterial drug-
binding site affect antibiotic susceptibility and/or resistance development. Structures of 
antibiotics bound to the ribosome have primarily been resolved from extremophilic bacteria 
such as Thermus thermophilus, Deinococcus radiodurans or Haloarcula morismortui (5, 11, 
28). Most genetic and biochemical data, however, have been generated in E. coli and M. 
smegmatis (2, 4, 7).  
It has still to be established whether the conclusions drawn from diverse model organisms 
hold true for other bacterial clades as well. To address this question, we introduced rRNA 
alterations corresponding to phylogenetic sequence variations that are found in bacteria and 
which locate to two major drug binding sites, the 23S-rRNA peptidyl transferase region and 
the 16S-rRNA decoding region. We used a previously described procedure for rRNA 
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mutagenesis in M. smegmatis which results in homogenous populations of mutant ribosomes 
in an otherwise isogenic background (14). The resulting recombinants were then tested for 
drug susceptibility by determining minimal inhibitory concentrations, MIC (14). 
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Phylogenetic sequence variations in the 23S rRNA peptidyl-transferase region  
Most rRNA nucleotides in the inner peptidyl-transferase region of the large ribosomal subunit 
are phylogenetically conserved (10). The macrolide/ketolide family of antibiotics binds to a 
hydrophobic cleft formed by residues 2058, 2059 and 2611 (E. coli numbering used 
throughout) in domain V of 23S-rRNA (see Figure 1) with some drugs making additional 
contacts in domain II (11, 12, 28). The adenines at 23S-rRNA positions 2058 and 2059 are 
phylogenetically conserved in bacteria and play an important role in compound binding, 
emerging of resistance and drug selectivity (1, 3, 27).  
  
U
U
U
U
U
AAA
A
A
A
A
G
G
G
G
G
G
G
G
C
C
C
C
C
CCCC
C C
CA
G A
A
A
U
UCGG
G G G G
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Secondary structure of domain V of the 23S rRNA. rRNA residues are 
numbered according to their homologous positions in E. coli 23S rRNA. Base pair 
2057-2611 is represented in blue and the adenine at position 2058 in red. 
 
One key interaction appears to be the hydrogen bond between the N1 of A2058 and the 2’-
hydroxyl group of the macrolides’ desosamine sugar (28, 30). Mutation of A2058 to a 
guanine (A2058G) greatly impairs the binding of macrolides to ribosomes by both chemical 
and sterical alteration of the binding site (11, 23). Ribosomal susceptibility to macrolides and 
ketolides is also determined by proper Watson-Crick base pairing between nucleotides at 
positions 2057 and 2611 (8), which are typically G-C in Proteobacteria and A-U in 
Mycobacteria (Figure 1). The respective nature of the 2057-2611 base pair has been shown 
to affect the resistance phenotype of the A2058G mutation towards ketolides (20). However, 
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the potential effect of an A2057G-U2611C substitution on ribosomes with an A2058 has 
remained elusive. Changing the A2057-U2611 base pair in M. smegmatis to G2057-C2611 
as it is typically found in Proteobacteria had no effect on susceptibility to any of the 
macrolides or ketolides tested (Table 1). Similarly, the nature of this base pair had no effect 
on resistance to 14-membered erythromycin and clarithromycin, 15-membered azithromycin 
and 16-membered spiramycin, tylosin and josamycin macrolides when combined with the 
A2058G mutation. However, we confirmed that the ketolide-resistance phenotype of the 
A2058G is indeed dependent on the nature of the 2057-2611 base-pair, as the A2058G 
mutant is 16-fold more susceptible to telithromycin in the context of a proteobacterial G2057-
C2611 sequence than in the context of a mycobacterial A2057-U2611 (Table 1).  
 
Clade homology 23S rRNA MIC (μg/mL) 
 2058 2057–2611 Ery Cla Azm Spm Tyl Jsm Tel 
Mycobacteria A A=U 8 1 4-8 2 2 2 0.25-0.5 
Proteobacteria A G≡C 8-16 1 2-4 1 2 1 0.25-0.5 
Mycobacteria G A=U > 512 > 512 > 512 128 8 8 128 
Proteobacteria G G≡C > 512 > 512 > 512 64 4 8 8 
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Table 1: Minimal inhibitory concentrations of various macrolides/ketolides in 
M. smegmatis 23S rRNA variants. Ery: erythromycin; Cla: clarithromycin; Azm: 
azithromycin; Spm: spiramycin; Tyl: tylosin; Jsm: josamycin; Tel: telithromycin 
 
 
Phylogenetic sequence variations in 16S rRNA helix 44 
Nucleotides of 16S-rRNA helices 18, 34 and 44 form the core aminoacyl tRNA acceptor site 
(A-site) and are highly conserved (9), reflecting their importance in mRNA decoding. 
Aminoglycoside antibiotics bind to the A-site by direct contacts to helix 44 and induce 
misreading of the genetic code (5, 6). While aminoglycosides form a number of hydrogen 
bonds with different nucleotides in helix 44, their interactions with rRNA residues 1408, 1409 
and 1491 (E. coli numbering) appear to be most critical for drug binding (14, 16, 17, 21).  
16S-rRNA residue 1408 is an adenine in all bacteria (Figure 2). Among all A-site mutations 
that confer aminoglycoside resistance, the 1408 adenine to guanine mutation is the 
predominant alteration in clinical drug resistant strains (25, 26). This transition mutation alone 
is sufficient to impart high level resistance to 6’-NH2 aminoglycosides (Table 2), by disrupting 
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the interaction between A1408 and the compound’s ring 1 aminosugar (22). It is also 
believed to function as the main specificity determinant of aminoglycosides, because higher 
eukaryotes carry a guanine at this position (3).   
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Figure 2: Secondary structure of 16S rRNA helix 44 decoding site. rRNA residues are 
numbered according to their homologous positions in E. coli 16S rRNA. Phylogenetic 
sequence variations analyzed in this study are represented in blue, the adenine at 
position 1408 in red. 
 
Minor sequence variations occur within the aminoglycoside-binding pocket of helix 44 
involving 16S-rRNA base-pair 1409-1491(9). The majority of eubacteria are characterized by 
a 1409 pyrimidine-1491 purine (C-G) interaction, compared to Propionibacteria which carry a 
1409 purine-1491 pyrimidine (A-U) base pair (Figure 2). Substituting the C-G base pair in M. 
smegmatis with a propionibacterial A-U considerably reduced susceptibility to all 4,5 and 4,6 
aminoglycosides tested (Table 2). This observation is in agreement with the lower 
aminoglycoside susceptibility of Propionibacteria (18); amikacin is the least affected because 
its L-haba group interacts with additional nucleotides within helix 44 and stabilizes drug 
binding (19). Combining the 1409A-1491U interaction further with an A1408G alteration 
resulted in high-level resistance to all aminoglycosides including paromomycin, a 6’-OH 
substituted 4,5 aminoglycoside  (Table 2).  The high-level resistance phenotype to 
paromomycin is apparently a combined effect of perturbing contacts to both G1491 and 
A1408, which would be in agreement with previous data demonstrating that U1491 increased 
resistance towards 6’-OH aminoglycosides such as paromomycin (21). 
To study the contribution of a 1409-1491 purine/pyrimidine switch to aminoglycoside 
susceptibility in the presence of a wt 1408A in more detail we introduced base pairs G-C and 
U-A. Base pair 1409U-1491A is a pyrimidine-purine interaction similar to the C-G found in the 
majority of eubacteria. Introduction of the U-A base-pair decreased susceptibility to 4,5-
aminoglycosides, in particular to paromomycin, but had virtually no effect on susceptibility to 
4,6-compounds (Table 2). Introduction of a purine-pyrimidine G-C interaction similar to the A-
U found in Propionibacteria, with the exception of amikacin, however, resulted in significant 
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158 
resistance to 4,5-and 4,6-aminoglycosides with the 4,5-compounds being more affected 
(Table 2). In line with our previous investigations and the different orientiaton of the 
aminoglycosides’ sugars linked to position 5 or 6 of the neamine core (20), these results 
demonstrate that in general the 4,5-compounds and in particular the 6’-OH paromomycin are 
more dependent on a proper 1409-1491 interaction than the 4,6-compounds. From our data 
we infer that in the presence of a 1408A there is a gradient of susceptibility for the 1409-1491 
interaction, i.e. C-G > U-A > G-C > A-U indicating that both the purine/pyrimidine interaction 
and the specific nucleotide are relevant.  
 
16S rRNA residues MIC (μg/mL) 
6’-OH 6’-NH2 Clade homology 
1408 1409–1491 
1410–
1490 
1411–
1489 
Pm Nm Gm Tb Km Ak 
Actinomycetales A C≡G G≡C U=A 1 0.5 1 1 1 0.5 
Proteobacteria A C≡G A=U C≡G 1 0.5 0.5-1 0.5-1 0.5 0.5 
Propionibact. A A=U G≡C U=A 64 8-16 16 32 16 2 
- A U=A G≡C U=A 8-16 1-2 1 2 1 0.5 
- A G≡C G≡C U=A 32 2-4 4 4 2 0.5 
Actinomycetales G C≡G G≡C U=A 64 > 1024 > 1024 > 1024 > 1024 > 1024 
Proteobacteria G C≡G A=U C≡G 64 > 1024 > 1024 1024 > 1024 > 1024 
Propionibacteria G A=U G≡C U=A > 1024 > 1024 > 1024 > 1024 > 1024 > 1024 
159 
160 
161 
162 
163 
164 
165 
166 
167 
168 
169 
170 
171 
172 
173 
 
Table 2: Minimal inhibitory concentrations of various aminoglycosides in M. 
smegmatis 16S rRNA variants. Pm, paromomycin; Nm, neomycin; Gm, gentamicin; Tb, 
tobramycin; Km, kanamycin A; Ak, amikacin 
 
Previously, limitations in genetic manipulation did not allow studying the effect of the bacterial 
1409-1491 polymorphism on aminoglycoside susceptibility in isogenic mutants. Rather, 
investigations were limited to testing different bacterial species representative of the 
corresponding sequence polymorphism. In these early studies it was concluded that the 
C1409-G1491 to A1409-U1491 polymorphism is not associated with resistance (21). Using 
more recently developed genetic techniques we have now been able to refine this statement 
and to define the role of the 1409-1491 base-pairing polymorphism in aminoglycoside 
susceptibility more precisely.  
We have recently found that the 16S rRNA interaction 1410-1490 may have a subtle 
influence on aminoglycoside susceptibility in ribosomes with a non Watson-Crick 1409-1491 
 
45
174 
175 
176 
177 
178 
179 
180 
181 
182 
183 
184 
185 
186 
187 
188 
189 
190 
191 
192 
193 
194 
195 
196 
197 
198 
199 
200 
201 
202 
203 
204 
205 
206 
207 
208 
209 
210 
211 
212 
213 
214 
215 
interaction, e.g. 1409C-1491C (15). In the current study, base pair variations in 1410-1490 
did not affect aminoglycoside susceptibility (Table 2). We conclude that in the presence of a 
1409-1491 base-pairing, the nature of 1410-1490 Watson-Crick base pair does not affect 
aminoglycoside susceptibility. 
The ribosome is target for many different classes of antibiotic compounds (13, 24). Minor 
structural differences, such as species-specific compositions of the drug binding site may 
affect susceptibility and resistance to drugs interfering with bacterial protein synthesis. From 
our results we conclude that natural sequence variations in the ribosomal PTC of bacteria do 
not affect drug susceptibility, but impact on the resistance phenotype of the A2058G mutation, 
in particular to the ketolide telithromycin.  In contrast, natural sequence variations in the 
ribosomal A site of bacteria affect species-specific drug susceptibility, but do not impact on 
the resistance phenotype of the A1408G mutation to 6’-NH2 aminoglycosides. In the past 
decade, atomic resolution structures of numerous ribosome-drug complexes have become 
available (34). A multi-pronged approach combining genetics, biochemistry and structural 
data should facilitate the modification of existing and evaluation of newer anti-microbial drugs. 
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